Torsion Dystonia 6

Mendelian MONDO:0011264 Pathograph 21 Show in embeddings browser Isolated dystonia Monogenic dystonia

An autosomal dominant isolated dystonia with markedly reduced penetrance, caused by heterozygous variants in THAP1. It was the first dystonia attributed to a transcription factor, and that is still the defining fact about its mechanism: THAP1 is a THAP-domain zinc-finger DNA-binding protein, so the primary lesion is a failure of gene regulation rather than of a channel, an enzyme, or a structural protein. The chain that follows is unusually well characterised at its molecular end and unusually poorly closed at its clinical end, and this entry is built to show that asymmetry rather than to paper over it. Reduced THAP1 DNA binding and disrupted cofactor recruitment lead to broad transcriptional dysregulation, executed substantially through the SP1 and SP4 transcription factors and in a cell-type-dependent way. Downstream of that, patient-derived striatal medium spiny neurons show reduced GABA-A receptor alpha2 expression and decreased GABAergic transmission, which is a concrete cellular defect measured in human cells. What is not established is the step from there to dystonic movement: the basal ganglia and cerebellar network dysfunction that is presumed to intervene is supported by imaging and by rodent circuit findings, not by a demonstrated causal path in humans. Two features make this entry worth reading carefully. First, the mouse does not get the disease. Germline Thap1 deletion is embryonic lethal, and the heterozygote - the genotype that should model human haploinsufficiency - has no discernable phenotype, because the mouse upregulates the remaining allele. Conditional nervous-system deletion produces locomotor deficits but still no dystonia. That is recorded structurally, as a FAILS_TO_RECAPITULATE model link and a HUMAN_MODEL_MISMATCH discussion, rather than as a caveat in prose. Second, whether a genotype-phenotype correlation exists is contested, and this entry records the disagreement rather than picking a side. A 2011 systematic review of 56 published THAP1 families reports no such relationship. A later screen of more than 1800 subjects reports the opposite: truncating variants and missense variants inside the THAP domain manifest earlier and spread further than variants elsewhere in the gene. The larger and later study is not obviously wrong, so the entry states both and makes no variant-specific severity claim of its own. Relationship to the existing Cervical_Dystonia entry: that entry covers common adult-onset sporadic focal cervical dystonia, deliberately binds no causal gene, and types THAP1 as SUSCEPTIBILITY because these genes explain a small minority of unselected cases. This entry is the Mendelian entity itself - one gene, dominant transmission, characteristic early-onset craniocervical and laryngeal involvement with limb spread. They are different diseases that share a phenotypic region. No pathophysiology node declares conforms_to. kb/modules/ was searched and no module covers transcription-factor haploinsufficiency or basal ganglia motor network imbalance.

Ask OpenScientist

Ask a research question about Torsion Dystonia 6. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
7
Phenotypes
2
Gaps
21
Pathograph
1
Genes
3
Medical Actions
4
Models
1
Deep Research
👪

Inheritance

1
Autosomal dominant with reduced penetrance HP:0000006
Heterozygous THAP1 variants segregate dominantly, but many carriers never develop dystonia. Reduced penetrance means an unaffected transmitting parent is common and a negative family history does not exclude the diagnosis.
Autosomal dominant
Show evidence (2 references)
PMID:19182804 SUPPORT Human Clinical
"We report the discovery of a mutation in the THAP1 gene in three Amish-Mennonite families with mixed-onset primary torsion dystonia (also known as DYT6 dystonia)."
The original family-based identification of THAP1 as the DYT6 locus.
PMID:21793105 SUPPORT Human Clinical
"account for a substantial proportion of familial, early-onset, nonfocal, primary dystonia cases"
Confirms familial transmission across many independent reports.
?

Discussions and Knowledge Gaps

2
No unprovoked Thap1 mouse develops dystonia, yet a nerve-injured heterozygote does. What does the need for a second hit imply about the proposed causal chain from transcriptional dysregulation to dystonic movement?
HUMAN MODEL MISMATCH OPEN dyt6_mouse_does_not_get_dystonia
Attached to
pathophysiology#Basal Ganglia and Cerebellar Motor Network Dysfunction animal_models#Mouse
This is a mismatch rather than a gap, because the model evidence exists and is informative - it simply does not reproduce the phenotype that defines the disease. Three things are established in mouse: germline Thap1 deletion is embryonic lethal; the heterozygote is rescued by autoregulatory upregulation of the intact allele and has no phenotype; and conditional deletion in neural precursors produces locomotor deficits and a dystonia-related transcriptional signature but not dystonia. The mismatch is mechanistically meaningful in two ways. First, the autoregulatory rescue is a species difference in gene-dosage handling, which means mouse cannot be used to test a haploinsufficiency hypothesis for this gene at all. Second, and more consequentially, the step in this entry's pathograph from network dysfunction to dystonia is the step no model has closed unprovoked: the conditional mouse reaches the network node and stops. Human iPSC-derived striatal neurons reach the cellular node and cannot, being a dish, address circuit output. That framing needs qualifying, and the qualification is the interesting part. A peripheral nerve crush in the heterozygote does produce dystonia-like movements, exceeding both naive heterozygotes and injured wild-types. So the genotype is not phenotypically silent; it is latent. The unanswered question shifts from "why does the mouse never get it" to "what does the second hit supply". That reframes the human question too, since penetrance in carriers is only 40 to 60 per cent, and it is the reason this entry now records the gene-environment link on the heterozygous model rather than only the failure. What remains genuinely unclosed is whether the injury acts through this entry's chain at all. The multi-omic differences reported in nerve-injured heterozygotes are energy-metabolism signatures in cerebellum, striatum and cortex, which is not obviously the SP1-mediated transcriptional route this pathograph models. The final causal edge is therefore still marked inferred.
Proposed experiments
Knock-in of a patient THAP1 missense allele in a model without Thap1 autoregulation
dyt6_reduced_dosage_without_autoregulation
Test whether the absent phenotype is due to the autoregulatory rescue rather than to a deeper difference in motor circuitry, by using a model organism in which the compensating upregulation does not occur, or by engineering an allele that escapes autoregulation.
Would support
pathophysiology#Basal Ganglia and Cerebellar Motor Network Dysfunction
Supporting outcome
  • Dystonic posturing emerges in an animal carrying a reduced-dosage THAP1 state that is not autoregulatorily rescued, closing the step from network dysfunction to dystonia.
Refuting outcome
  • A genuinely reduced-dosage animal still shows locomotor deficit without dystonia, which would argue that the human phenotype depends on features of primate motor circuitry rather than on THAP1 dosage alone.
Show evidence (2 references)
PMID:30590536 SUPPORT Model Organism
"Although these mice do not exhibit dystonia, they show pronounced locomotor deficits reflecting derangements in the cerebellar and basal ganglia circuitry."
The core statement of the mismatch: circuit derangement is reproduced, the defining clinical phenotype is not.
PMID:30590536 SUPPORT Model Organism
"This is because mice show autoregulation of Thap1 mRNA levels with upregulation at the non-affected locus."
Identifies the species difference that makes the heterozygous model uninformative, which is the first half of the mismatch.
Why is there no genotype-phenotype correlation in THAP1 dystonia, and what determines penetrance?
KNOWLEDGE GAP OPEN dyt6_no_genotype_phenotype_correlation
Attached to
genetic#THAP1 pathophysiology#Isolated Dystonia
More than eighty variants are known across several functional classes - DNA-binding missense, protein-destabilising missense, HCFC1-binding-motif missense, and truncating alleles. Whether they predict phenotype is disputed rather than settled: the 2011 review of 56 families found no relationship, while a later screen of more than 1800 subjects found that truncating and THAP-domain missense variants manifest earlier and involve more body regions. Both are cited in the genetic section. Either way the molecular assays curated in this entry do not by themselves predict who becomes ill or how severely. Penetrance is incomplete at 40 to 60 per cent, so something other than the THAP1 allele decides whether a carrier develops dystonia. The environmental second hit is no longer purely speculative: a peripheral nerve crush unmasks dystonia-like movements in the heterozygous mouse, which is a demonstration in principle that a trigger can convert a silent genotype into a phenotype. It is not a human exposure, and no precipitant is established in carriers, so the practical counselling question stays open.
Show evidence (2 references)
PMID:21793105 SUPPORT Human Clinical
"Currently, 56 families present with a THAP1 mutation; however, no genotype/phenotype relationship has been found."
States the absence of correlation across the published family set.
PMID:32112337 SUPPORT In Vitro
"Taking together, the current study showed different potential pathogenic mechanisms of THAP1 mutations which lead to the same consequence of DYT6 dystonia."
Supports the convergence of mechanistically distinct variant classes on one clinical outcome, which is what makes the absence of correlation coherent rather than merely unexplained.
⚙

Pathophysiology

7
Heterozygous THAP1 Loss-of-Function Variants
Heterozygous variants in THAP1, most often missense changes affecting the N-terminal THAP DNA-binding domain, but also frameshift and nonsense alleles. More than eighty variants have been reported and about two thirds are missense. Different variant classes reach the same endpoint by different routes: some abolish DNA binding, some destabilise the protein, and some leave DNA binding intact while abolishing cofactor recruitment.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Genetic context variant_origin: GERMLINE functional_impact_category: LOSS_OF_FUNCTION
Downstream
Reduced THAP1 Transcriptional Regulatory Function Loss of DNA binding, loss of protein stability, or loss of cofactor recruitment each reduce the amount of functional THAP1 regulatory activity at target promoters.
Show evidence (2 references)
PMID:32112337 SUPPORT INDIRECT In Vitro
"Until now, more than eighty different mutations in THAP1 gene have been found in patients with primary dystonia, and two third of them are missense mutations."
Quantifies the variant spectrum and the predominance of missense change. Graded IN_VITRO because evidence_source classifies the publication, and this publication is a cell-based study: SK-N-AS and HEK293 transfection, patient fibroblast immunoblot, microarray, ChIP-seq and promoter luciferase assays. Cached MeSH is Cell Line Tumor, Cells Cultured, HEK293 Cells, Fibroblasts and Neurons. Marked INDIRECT because the quoted sentence is the paper's own introduction summarising the published mutation spectrum rather than a result it measures. The same PMID is graded IN_VITRO at four other sites in this file.
PMID:19182804 SUPPORT In Vitro
"We demonstrate that the missense mutation impairs DNA binding, suggesting that transcriptional dysregulation may contribute to the phenotype of DYT6 dystonia."
Shows the functional consequence of a disease missense variant on DNA binding. Graded IN_VITRO because the DNA-binding demonstration is a biochemical assay, while the family identification in the same paper is clinical.
Reduced THAP1 Transcriptional Regulatory Function
The convergence point of the variant classes. THAP1 is a zinc-finger transcription factor, and disease variants reduce its regulatory output either by impairing sequence-specific DNA binding, by reducing protein stability and so effective dosage, or by abolishing recruitment of the HCFC1 cofactor at promoters THAP1 still binds. The last of these is the reason a variant can be pathogenic with normal DNA binding.
sequence-specific DNA binding by the THAP zinc-finger domain GO:0043565 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased sequence-specific DNA binding by the THAP zinc-finger domain, annotated with sequence-specific DNA binding (GO:0043565). GO:0043565 is a molecular function from the Gene Ontology. ↓ DECREASED
Experimental models
THAP1 mutant stable neuronal cell lines CELL LINE Measures the transcriptional and protein-stability consequences of individual patient missense variants.
Animal models
Thap1 heterozygous knockout mouse Mouse fails to recapitulate The model fails at the first node it is meant to reproduce: transcriptional autoregulation restores Thap1 message, so the haploinsufficient state the human disease depends on is not established.
Downstream
Transcriptional Dysregulation Through the SP1 Family Reduced THAP1 regulatory function propagates into a much wider expression change than its own direct target set, because it acts through other transcription factors.
Derepression of TOR1A THAP1's best-characterised direct target. Wild-type THAP1 represses the TOR1A promoter, so reduced THAP1 function releases that repression. This is the specific, measured arm of the transcriptional lesion, as distinct from the broad SP1-mediated arm above.
Show evidence (3 references)
PMID:28486698 SUPPORT In Vitro
"We investigated the consequences of these mutations on the interaction of THAP1 with HCFC1 and demonstrated that all three mutations abolished HCFC1-THAP1 complex formation."
Shows a distinct loss-of-function route: three patient variants in the HCFC1-binding motif abolish cofactor recruitment.
PMID:28486698 SUPPORT INDIRECT In Vitro
"Quantitative ChIP on selected promoters revealed that none of the mutations significantly decreased the DNA-binding ability of THAP1 while HCFC1 binding was highly reduced."
Establishes that this route is independent of DNA binding. Marked INDIRECT because it supports the node by excluding the alternative mechanism rather than by measuring regulatory output directly.
PMID:32112337 SUPPORT In Vitro
"In addition, we show that some THAP1 mutations (C54Y and F81L) decrease the protein stability which might also be responsible for altered transcription regulation due to dosage insufficiency."
Documents the protein-stability route to reduced regulatory function.
Derepression of TOR1A
THAP1 binds the core promoter of TOR1A and represses it; DYT6-associated mutant THAP1 represses it less. TOR1A is the gene mutated in DYT1 dystonia, so this is the molecular link between the two commonest monogenic isolated dystonias, and it is the reason a transcription-factor disease and a torsinA-protein disease can converge on one clinical syndrome. Recorded as a distinct node rather than folded into the SP1 arm because the binding is direct and demonstrated by promoter assay and ChIP, whereas the SP1 arm is an indirect expression-level effect. No downstream edge is asserted from here: how much of the dystonia is attributable to TOR1A derepression rather than to the wider expression change is not established by the curated evidence.
repression of the TOR1A core promoter by THAP1 GO:0000976 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased repression of the TOR1A core promoter by THAP1, annotated with transcription cis-regulatory region binding (GO:0000976). GO:0000976 is a molecular function from the Gene Ontology. ↓ DECREASED
Show evidence (2 references)
PMID:20976771 SUPPORT In Vitro
"Further, we report that wild type THAP1 represses the expression of TOR1A, whereas dystonia 6-associated mutant THAP1 results in decreased repression of TOR1A."
States both the normal repressive function and the direction of its loss in disease-associated mutants, which is the whole claim of this node.
PMID:20865765 SUPPORT In Vitro
"Using electromobility shift assays and chromatin immunoprecipitation (ChIP) quantitative polymerase chain reaction (qPCR), we demonstrate a physical interaction between THAP1 and the TOR1A promoter that is abolished by pathophysiologic mutations."
Independent demonstration of the physical interaction and its loss, by two methods, which is what makes this a direct target rather than a correlated expression change.
Transcriptional Dysregulation Through the SP1 Family
THAP1 turns out to account directly for only a minority of the genes that change when it is mutated. The bulk of the effect runs through the SP1 family transcription factors SP1 and SP4, and it is cell-type dependent - which is a plausible part of why a ubiquitously expressed transcription factor produces a disorder confined to motor control.
regulation of transcription by RNA polymerase II GO:0006357 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated regulation of transcription by RNA polymerase II (GO:0006357). GO:0006357 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Reduced Striatal GABAergic Transmission Among the dysregulated gene sets are those governing synaptic transmission, and the measured consequence in patient-derived striatal neurons is a GABAergic deficit.
Basal Ganglia and Cerebellar Motor Network Dysfunction Transcriptional changes affecting nervous system development and synaptic transmission are the proposed origin of the circuit-level abnormality. Supported in rodent models rather than demonstrated in humans.
Show evidence (3 references)
PMID:35015830 SUPPORT In Vitro
"THAP1 mutations lead to dysregulation of genes mainly through regulation of SP1 family members, SP1 and SP4, in a cell type dependent manner."
States the SP1/SP4 route and its cell-type dependence, which is the core claim of this node.
PMID:35015830 SUPPORT In Vitro
"We observed that THAP1 targeted only a minority of differentially expressed genes caused by its mutation."
Supports the claim that most of the expression change is indirect rather than at THAP1's own binding sites.
PMID:32112337 SUPPORT In Vitro
"ChIP-seq showed that THAP1 can bind to the promoter of one of these genes, superoxide dismutase 2 (SOD2)."
An example of a directly bound target gene, complementing the indirect SP1-family route.
Reduced Striatal GABAergic Transmission
The most concrete cellular defect demonstrated in human cells. Patient-derived striatal medium spiny neurons show downregulation of the GABA-A receptor alpha2 subunit, lower calcium responses to GABA, and reduced miniature postsynaptic current frequency, with an increased rate of spontaneous action potentials - that is, disinhibition and hyperexcitability.
striatal medium spiny neuron CL:1001474 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves striatal medium spiny neuron, annotated with medium spiny neuron (CL:1001474). CL:1001474 is a cell type from the Cell Ontology.
synaptic transmission, GABAergic GO:0051932 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased synaptic transmission, GABAergic (GO:0051932). GO:0051932 is a biological process from the Gene Ontology. ↓ DECREASED
Experimental models
Patient-derived iPSC striatal medium spiny neurons IPSC DERIVED MODEL Directly measures the GABAergic deficit in the cell type and species the node is about.
Downstream
Basal Ganglia and Cerebellar Motor Network Dysfunction Disinhibited, hyperexcitable striatal projection neurons are the proposed cellular substrate of abnormal basal ganglia output.
Show evidence (2 references)
PMID:34095114 SUPPORT In Vitro
"Calcium imaging and quantitative PCR analysis revealed significantly lower Ca2+ amplitudes upon GABA applications and a marked downregulation of the gene encoding the GABA A receptor alpha2 subunit in THAP1 MSNs indicating a decreased GABAergic transmission."
Measures the GABAergic deficit in patient-derived neurons, which is the claim of this node.
PMID:34095114 SUPPORT In Vitro
"Whole-cell patch-clamp recordings showed a significantly lower frequency of miniature postsynaptic currents (mPSCs), whereas the frequency of spontaneous action potentials (APs) was elevated in THAP1 MSNs suggesting that decreased synaptic activity might have resulted in enhanced generation of APs."
Documents the electrophysiological disinhibition and hyperexcitability described in this node.
Basal Ganglia and Cerebellar Motor Network Dysfunction
The least resolved step, and the entry says so. Abnormal output from basal ganglia-thalamo-cortical loops, with a parallel cerebellar contribution, is the standard account of how a striatal cellular defect becomes dystonic movement. The human evidence is structural imaging showing damaged axonal integrity in sensorimotor white matter; the circuit-level causal account comes from rodent models, which do not reproduce the human phenotype. No human study curated here demonstrates the causal step from this node to dystonia.
basal ganglion UBERON:0002420 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in basal ganglion (UBERON:0002420). UBERON:0002420 is an anatomical location from the Uberon multi-species anatomy ontology. cerebellum UBERON:0002037 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebellum (UBERON:0002037). UBERON:0002037 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
Nestin-conditional Thap1 knockout mouse Mouse partially recapitulates Reproduces circuit-level derangement in the cerebellar and basal ganglia pathways, and the transcriptional signature, without reproducing the disease's defining motor phenotype.
Downstream
Isolated Dystonia Aberrant sensorimotor integration and loss of surround inhibition are the proposed proximate cause of the dystonic posture and movement. This edge is inferred rather than demonstrated.
Show evidence (2 references)
PMID:22652465 SUPPORT Human Clinical
"The axonal integrity and coherence in the region of sensorimotor area of the brain was damaged in DYT6 dystonia."
Human diffusion tensor imaging evidence of a sensorimotor white-matter abnormality in genotyped patients. Note that the same abstract's results sentence attributes the fractional anisotropy reduction to "DYT1 carriers" while the study enrolled DYT6 patients; the conclusion sentence quoted here is the unambiguous statement and is used for that reason.
PMID:30590536 SUPPORT INDIRECT Model Organism
"Although these mice do not exhibit dystonia, they show pronounced locomotor deficits reflecting derangements in the cerebellar and basal ganglia circuitry."
Supports involvement of cerebellar and basal ganglia circuitry, and is marked INDIRECT for the strongest possible reason: the same sentence records that the model does not produce dystonia, so it bears on the circuit claim without bearing on the step to the clinical phenotype.
Isolated Dystonia
The clinical endpoint: sustained or intermittent involuntary muscle contractions producing abnormal postures and repetitive movements, with no other neurological sign. Onset is typically in childhood or adolescence, most often craniocervical or laryngeal, with spread to the limbs. Penetrance is incomplete, so this node is reached by only a fraction of carriers.
Animal models
Thap1 heterozygous knockout mouse Mouse partially recapitulates After a peripheral nerve crush, the heterozygote produces dystonia-like movements exceeding both naive heterozygotes and injured wild-type animals. The genotype supplies the predisposition and the injury supplies the trigger, which is a two-hit model of the incomplete penetrance seen in human carriers.
Downstream
Torticollis
Laryngeal dystonia
Dysarthria
Writer's cramp
Oromandibular dystonia
Blepharospasm
Generalized dystonia
Show evidence (2 references)
PMID:20825472 SUPPORT Human Clinical
"Whilst in the DYT6 cases, the onset was cranial or cervical and progresses very slowly."
Describes the characteristic onset distribution and tempo that distinguish this entity from DYT1 dystonia.
PMID:21793105 SUPPORT Human Clinical
"Therefore, we carried out a systematic review of the literature on the THAP1 gene to colligate all reported patients with a specific THAP1 mutation and the associated clinical signs in order to describe the broad phenotypic continuum of this disorder."
Establishes that the clinical picture is a continuum rather than a single stereotyped presentation.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Torsion Dystonia 6 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Head and Neck 2
Torticollis HP:0000473 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cervical dystonia, annotated with Torticollis (HP:0000473). HP:0000473 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20825472 SUPPORT Human Clinical
"Whilst in the DYT6 cases, the onset was cranial or cervical and progresses very slowly."
Reports cervical onset as one of the characteristic presentations.
Blepharospasm HP:0000643 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Blepharospasm (HP:0000643). HP:0000643 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20825472 SUPPORT INDIRECT Human Clinical
"the cranial involvement in DYT6"
Supports cranial involvement, of which blepharospasm is a manifestation. Marked INDIRECT because the quote names the region rather than the sign.
Nervous System 5
Laryngeal dystonia HP:0012049 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasmodic dysphonia, annotated with Laryngeal dystonia (HP:0012049). HP:0012049 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:21793105 SUPPORT INDIRECT Human Clinical
"The identification of a larger number of THAP1 mutations and collection of high-quality clinical information for each described mutation through international collaborative effort will help investigating the structure-function and genotype-phenotype correlations in DYT6 dystonia."
Marked INDIRECT and worth reading as such. The systematic review this quote comes from is the entry's source for the phenotypic continuum that includes laryngeal involvement, but the abstract does not enumerate the individual body regions, so no quote in the cached record asserts laryngeal dystonia directly. Recorded honestly rather than supported by a quote that does not say it.
Dysarthria HP:0001260 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysarthria (HP:0001260). HP:0001260 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20825472 SUPPORT INDIRECT Human Clinical
"CONCLUSION: The major clinical differences between DYT1 and DYT6 dystonia in China were the cranial involvement in DYT6 and progress to general dystonia within several years in DYT1."
Supports cranial involvement, of which dysarthria is a manifestation. Marked INDIRECT because the quote names the region rather than the symptom.
Writer's cramp HP:0002356 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Task-specific upper limb dystonia, annotated with Writer's cramp (HP:0002356). HP:0002356 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:21793105 SUPPORT INDIRECT Human Clinical
"Currently, 56 families present with a THAP1 mutation; however, no genotype/phenotype relationship has been found."
Marked INDIRECT for the same reason as laryngeal dystonia: the cached abstract establishes a broad phenotypic continuum across 56 families without enumerating body regions. The region is clinically well described but is not asserted by any quote available in this entry's reference cache.
Oromandibular dystonia HP:0012048 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Oromandibular dystonia (HP:0012048). HP:0012048 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20825472 SUPPORT INDIRECT Human Clinical
"The major clinical differences between DYT1 and DYT6 dystonia in China were the cranial involvement in DYT6"
Supports cranial involvement, of which oromandibular dystonia is a manifestation. Marked INDIRECT because the quote names the region rather than the specific pattern.
Generalized dystonia HP:0007325 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized dystonia (HP:0007325), qualified as course progressive. HP:0007325 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:20825472 SUPPORT Human Clinical
"The clinical presentations of the DYT1 cases included onset in the limbs that could progress to the generalized dystonia within several years but without cranial involvement."
Establishes the contrasting DYT1 tempo against which this disorder's slower spread is described in the same study.
🧬

Genetic Associations

1
THAP1
Gene: THAP1 hgnc:20856 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is THAP1 (hgnc:20856). hgnc:20856 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (5 references)
PMID:21793105 SUPPORT Human Clinical
"THAP1 is the first transcriptional factor involved in primary dystonia and the hypothesis of a transcriptional deregulation, which was primarily proposed for the X-linked dystonia-parkinsonism (DYT3 dystonia), provided thus a new way to investigate the possible mechanism underlying the..."
Establishes THAP1's identity as a transcription factor and the significance of that for the mechanism.
PMID:21793105 SUPPORT Human Clinical
"Currently, 56 families present with a THAP1 mutation; however, no genotype/phenotype relationship has been found."
States the absence of genotype-phenotype correlation recorded in the notes.
PMID:22377579 SUPPORT Human Clinical
"Protein truncating mutations and missense mutations within the THAP domain of THAP1 tend to manifest at an earlier age and exhibit more extensive anatomical distributions than mutations localized to other regions of THAP1."
Reports a variant-class effect on onset age and anatomical spread across more than 1800 subjects, which supports the THAP1 gene-disease relationship this record asserts. That it disagrees with the 2011 review quoted above is a disagreement between two sources, recorded in this record's notes and in the dyt6_no_genotype_phenotype_correlation discussion rather than by grading this item against a sibling item.
+ 2 more references
💊

Medical Actions

3
Oral pharmacotherapy
Action: oral pharmacotherapy for dystoniaNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is oral pharmacotherapy for dystonia, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Platform: Small molecule
The first tier of the dystonia treatment algorithm, used before chemodenervation and surgery: anticholinergics, baclofen and clonazepam, all off-label. A levodopa trial is standard in young-onset dystonia to exclude dopa-responsive dystonia, which is a different disease rather than a treatment for this one. Like everything else here it is symptomatic and does nothing about the transcriptional lesion.
Mechanism Target:
Isolated Dystonia — Acts on the motor endpoint by modulating cholinergic and GABAergic tone, downstream of every mechanistic node in this entry.
Show evidence (1 reference)
PMID:31117876 SUPPORT INDIRECT Human Clinical
"Oral anticholinergics, baclofen and clonazepam are used off-label, but novel drugs in development include sodium oxybate, zonisamide and perampanel."
Names the first-tier oral agents and records that their use is off-label. INDIRECT because the source is a dystonia-management review rather than a THAP1-genotyped study.
Botulinum toxin chemodenervation
Action: botulinum toxin chemodenervationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is botulinum toxin chemodenervation, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Platform: Other
Intramuscular botulinum toxin injection into the dystonic muscles, the standard symptomatic treatment for focal and segmental dystonia. It acts on the effector end of the chain and does nothing about the transcriptional lesion.
Mechanism Target:
Isolated Dystonia — Blocks acetylcholine release at the neuromuscular junction of the injected muscle, reducing the dystonic contraction. Symptomatic only, and downstream of every mechanistic node in this entry.
Show evidence (1 reference)
PMID:31117876 SUPPORT INDIRECT Human Clinical
"Chemodenervation with botulinum toxin remains the treatment of choice for focal- or select-body regions in generalized and segmental dystonia."
Establishes botulinum toxin as first-line for the focal and segmental distribution this disorder presents with. Marked INDIRECT because the source is a dystonia-management review and does not report a THAP1-genotyped cohort, so it supports the practice rather than an outcome in DYT6.
Deep brain stimulation of the globus pallidus internus
Action: deep brain stimulationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is deep brain stimulation (NCIT:C21024). NCIT:C21024 is a clinical intervention from the NCI Thesaurus. Ontology label: Deep Brain Stimulation NCIT:C21024
Platform: Device
Bilateral pallidal deep brain stimulation, used for medically refractory generalized or segmental dystonia. It intervenes at the network node rather than at the muscle, which makes it the one treatment in this entry that acts inside the pathograph rather than at its endpoint.
Mechanism Target:
Basal Ganglia and Cerebellar Motor Network Dysfunction — Modulates pallidal output, altering the abnormal basal ganglia-thalamo-cortical signalling proposed to generate the dystonia.
Show evidence (2 references)
PMID:31817799 SUPPORT Human Clinical
"All benefited from surgery: dystonia severity was reduced by a median of 58% (IQR 31-62, p = 0.001) at last follow-up, as assessed by the Burke Fahn Marsden movement subscale."
Reports the outcome in a genotyped THAP1 cohort, which is what makes this evidence about this disorder rather than about dystonia generally.
PMID:21949105 SUPPORT Human Clinical
"DYT6 patients appear to respond less robustly to GPi-DBS than their DYT1 counterparts, most likely reflecting differences in the underlying pathophysiology of these distinct genetic disorders."
Records the qualification that matters clinically: the response is real but weaker than in DYT1, and the authors attribute that to a genuinely different pathophysiology rather than to technique.
🧫

Experimental Models

2
Patient-derived iPSC striatal medium spiny neurons IPSC_DERIVED_MODEL
Medium spiny neurons differentiated from induced pluripotent stem cells of two THAP1 patients and one reduced-penetrance family member, compared with healthy controls. This is the human model that succeeds where the mouse fails, because it carries the patient genotype in human cells.
striatal medium spiny neuron CL:1001474 Cell Ontology (CL) Relation: this experimental model uses this cell type This experimental model uses striatal medium spiny neuron, annotated with medium spiny neuron (CL:1001474). CL:1001474 is a cell type from the Cell Ontology.
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Publication
PMID:34095114
Pathograph links
Reduced Striatal GABAergic Transmission recapitulates fidelity: moderate observes: cellular Directly measures the GABAergic deficit in the cell type and species the node is about.
Limitations: Derived from three individuals carrying two variants, so the finding is not established across the allelic spectrum. iPSC-derived neurons are developmentally immature relative to adult striatum, and the culture lacks the afferent and efferent connectivity in which the circuit-level claim would have to be tested.
Readouts
GABA-A receptor alpha2 subunit expression
Direction: DECREASED
Interpretation: Transcript-level correlate of the reduced GABAergic transmission at this node.
Show evidence (1 reference)
PMID:34095114 SUPPORT In Vitro
"a marked downregulation of the gene encoding the GABA A receptor alpha2 subunit in THAP1 MSNs"
Reports the direction and target of this measurement.
Miniature postsynaptic current frequency
Direction: DECREASED
Interpretation: Electrophysiological correlate of reduced synaptic transmission.
Show evidence (1 reference)
PMID:34095114 SUPPORT In Vitro
"Whole-cell patch-clamp recordings showed a significantly lower frequency of miniature postsynaptic currents (mPSCs)"
Reports the direction of this measurement.
Spontaneous action potential frequency
Direction: INCREASED
Interpretation: Hyperexcitability resulting from loss of inhibitory input.
Show evidence (1 reference)
PMID:34095114 SUPPORT In Vitro
"whereas the frequency of spontaneous action potentials (APs) was elevated in THAP1 MSNs"
Reports the direction of this measurement.
Show evidence (1 reference)
PMID:34095114 SUPPORT In Vitro
"induced pluripotent stem cell (iPSC)-derived medium spiny neurons (MSNs) from two patients and one family member with reduced penetrance carrying a mutation in the gene THAP1"
Establishes the model's construction and that it carries patient genotypes, which is why it is treated as informative for this node.
THAP1 mutant stable neuronal cell lines CELL_LINE
SK-N-AS neuroblastoma lines stably expressing wild-type or patient-derived mutant THAP1, used for transcriptional profiling and protein stability testing.
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Publication
PMID:32112337
Pathograph links
Reduced THAP1 Transcriptional Regulatory Function measures fidelity: moderate observes: molecular Measures the transcriptional and protein-stability consequences of individual patient missense variants.
Limitations: An overexpression system in a neuroblastoma line, so the dosage is not physiological and the cell type is not a striatal projection neuron. Two variants were profiled, so the shared 28-gene signature is not established across the allelic spectrum.
Show evidence (1 reference)
PMID:32112337 SUPPORT In Vitro
"Transcriptional profiling using microarrays revealed a set of 28 common genes dysregulated in two mutated THAP1 (S21T and F81L) overexpression cell lines suggesting a common mechanism of these mutations."
Reports the shared dysregulated gene set this model contributes.
🐁

Animal Models

2
Thap1 heterozygous knockout mouse
The genotype that should, in principle, model human THAP1 haploinsufficiency. Unprovoked, it does not: the mouse compensates by upregulating transcription from the intact allele and has no discernable phenotype. Given a second hit it does. After sciatic nerve crush, Thap1+/- mice show significantly more dystonia-like movements than naive Thap1+/- mice and than injured wild-type mice, so the genotype carries a real susceptibility that is invisible without a trigger. Both results are modelled below, as separate links, because they are claims about different nodes.
Species
Mouse
Genotype
Thap1 heterozygous null
Publication
PMID:30590536
Pathograph links
Reduced THAP1 Transcriptional Regulatory Function fails to recapitulate fidelity: low observes: molecular The model fails at the first node it is meant to reproduce: transcriptional autoregulation restores Thap1 message, so the haploinsufficient state the human disease depends on is not established.
Limitations: Thap1 mRNA is autoregulated in mouse, with upregulation at the non-affected locus, so heterozygous deletion does not produce a reduced-dosage state. Germline homozygous deletion cannot be used instead because it is embryonic lethal. The failure is a species difference in gene dosage compensation, not a limitation of the construct. This grading is about the molecular node only: the same animal does produce a dystonic phenotype after a peripheral nerve injury, which is recorded as a separate link below. Read together, the model is uninformative about steady-state THAP1 dosage and informative about gene-environment interaction.
Divergences from the human mechanism
species mismatch invalidating
Mouse compensates for the loss of one Thap1 allele by upregulating the remaining one. No comparable autoregulatory rescue is described in human carriers, who are symptomatic at the same genotype.
Show evidence (2 references)
PMID:30590536 REFUTE Model Organism
"While germ-line deletion of Thap1 is embryonic lethal, mice lacking one Thap1 allele-which in principle should recapitulate the haploinsufficiency of the human syndrome-do not show a discernable phenotype."
The authors' own statement that the model does not reproduce the human haploinsufficient state.
+ 1 more reference
Isolated Dystonia partially recapitulates fidelity: moderate observes: organism After a peripheral nerve crush, the heterozygote produces dystonia-like movements exceeding both naive heterozygotes and injured wild-type animals. The genotype supplies the predisposition and the injury supplies the trigger, which is a two-hit model of the incomplete penetrance seen in human carriers.
Limitations: The trigger is an experimental sciatic nerve crush, not an exposure reported in human DYT6, so the gene-environment interaction is demonstrated in principle rather than as the human mechanism. The readout is an automated movement classification rather than a clinical dystonia diagnosis, and the multi-omic differences reported alongside it are descriptive and not shown to be causal.
Divergences from the human mechanism
species mismatch qualifying
A peripheral nerve injury is not a recognised precipitant of human THAP1 dystonia. The claim this link supports is that a second hit can unmask the genotype, not that this particular second hit is the human one.
Show evidence (2 references)
PMID:39732371 SUPPORT Model Organism
"Phenotypic analysis using an unbiased deep learning algorithm revealed that nerve-injured Thap1+/- mice exhibited significantly more dystonia like movements (DLM) over the course of the 12-week experiment compared to naive Thap1+/- mice."
The genotype-dependent effect of the second hit, which is what licenses PARTIALLY_RECAPITULATES against the dystonia node.
+ 1 more reference
Show evidence (1 reference)
PMID:30590536 REFUTE Model Organism
"mice lacking one Thap1 allele-which in principle should recapitulate the haploinsufficiency of the human syndrome-do not show a discernable phenotype"
Attests that this model is not informative for the human disease at the genotype that matches it.
Nestin-conditional Thap1 knockout mouse
Deletion of Thap1 in neural precursors, used to get past the embryonic lethality of germline deletion and the autoregulatory rescue in heterozygotes. It produces locomotor deficits and transcriptional changes overlapping other dystonic syndromes, but still no dystonia.
Species
Mouse
Genotype
Thap1 conditional deletion in nestin-expressing glial and neuronal precursors
Publication
PMID:30590536
Pathograph links
Basal Ganglia and Cerebellar Motor Network Dysfunction partially recapitulates fidelity: moderate observes: organism Reproduces circuit-level derangement in the cerebellar and basal ganglia pathways, and the transcriptional signature, without reproducing the disease's defining motor phenotype.
Limitations: The model does not develop dystonia. Deletion is in neural precursors rather than a heterozygous point variant, so the genetic lesion is more severe and earlier than the human one, and the readout is locomotor deficit rather than dystonic posturing.
Divergences from the human mechanism
other qualifying
The model reaches the circuit node but not the clinical endpoint: locomotor deficits are observed, while sustained involuntary muscle contraction producing abnormal posture, which is what defines dystonia, is not. Typed OTHER because ModelDivergenceTypeEnum has no value for a model that reproduces the mechanism but not the phenotype; the nearest candidate discussed in CLAUDE.md, INCOMPLETE_PHENOTYPE, is named there as a likely future addition and is not currently a permissible value.
Show evidence (1 reference)
PMID:30590536 SUPPORT Model Organism
"Although these mice do not exhibit dystonia, they show pronounced locomotor deficits reflecting derangements in the cerebellar and basal ganglia circuitry."
States both the circuit finding this link records and the phenotypic limitation that caps its fidelity.
Show evidence (1 reference)
PMID:30590536 SUPPORT Model Organism
"These behavioral features are associated with alterations in the expression of genes involved in nervous system development, synaptic transmission, cytoskeleton, gliosis and dopamine signaling that link DYT6 to other primary and secondary dystonic syndromes."
Supports treating the model as informative for the transcriptional and circuit nodes, through the pathway overlap with other dystonic syndromes.
{ }

Source YAML

click to show 
name: Torsion Dystonia 6
creation_date: "2026-09-12T13:20:00Z"
category: Mendelian
synonyms:
- DYT6
- DYT6 dystonia
- DYT-THAP1
- THAP1 dystonia
- dystonia 6, torsion
- primary torsion dystonia, mixed type
description: >-
  An autosomal dominant isolated dystonia with markedly reduced penetrance,
  caused by heterozygous variants in THAP1. It was the first dystonia attributed
  to a transcription factor, and that is still the defining fact about its
  mechanism: THAP1 is a THAP-domain zinc-finger DNA-binding protein, so the
  primary lesion is a failure of gene regulation rather than of a channel, an
  enzyme, or a structural protein.

  The chain that follows is unusually well characterised at its molecular end and
  unusually poorly closed at its clinical end, and this entry is built to show
  that asymmetry rather than to paper over it. Reduced THAP1 DNA binding and
  disrupted cofactor recruitment lead to broad transcriptional dysregulation,
  executed substantially through the SP1 and SP4 transcription factors and in a
  cell-type-dependent way. Downstream of that, patient-derived striatal medium
  spiny neurons show reduced GABA-A receptor alpha2 expression and decreased
  GABAergic transmission, which is a concrete cellular defect measured in human
  cells. What is not established is the step from there to dystonic movement:
  the basal ganglia and cerebellar network dysfunction that is presumed to
  intervene is supported by imaging and by rodent circuit findings, not by a
  demonstrated causal path in humans.

  Two features make this entry worth reading carefully.

  First, the mouse does not get the disease. Germline Thap1 deletion is embryonic
  lethal, and the heterozygote - the genotype that should model human
  haploinsufficiency - has no discernable phenotype, because the mouse
  upregulates the remaining allele. Conditional nervous-system deletion produces
  locomotor deficits but still no dystonia. That is recorded structurally, as a
  FAILS_TO_RECAPITULATE model link and a HUMAN_MODEL_MISMATCH discussion, rather
  than as a caveat in prose.

  Second, whether a genotype-phenotype correlation exists is contested, and this
  entry records the disagreement rather than picking a side. A 2011 systematic
  review of 56 published THAP1 families reports no such relationship. A later
  screen of more than 1800 subjects reports the opposite: truncating variants and
  missense variants inside the THAP domain manifest earlier and spread further
  than variants elsewhere in the gene. The larger and later study is not
  obviously wrong, so the entry states both and makes no variant-specific severity
  claim of its own.

  Relationship to the existing Cervical_Dystonia entry: that entry covers common
  adult-onset sporadic focal cervical dystonia, deliberately binds no causal gene,
  and types THAP1 as SUSCEPTIBILITY because these genes explain a small minority
  of unselected cases. This entry is the Mendelian entity itself - one gene,
  dominant transmission, characteristic early-onset craniocervical and laryngeal
  involvement with limb spread. They are different diseases that share a
  phenotypic region.

  No pathophysiology node declares conforms_to. kb/modules/ was searched and no
  module covers transcription-factor haploinsufficiency or basal ganglia motor
  network imbalance.
disease_term:
  preferred_term: torsion dystonia 6
  term:
    id: MONDO:0011264
    label: torsion dystonia 6
parents:
- Isolated dystonia
- Monogenic dystonia
inheritance:
- name: Autosomal dominant with reduced penetrance
  inheritance_term:
    preferred_term: Autosomal dominant
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Heterozygous THAP1 variants segregate dominantly, but many carriers never
    develop dystonia. Reduced penetrance means an unaffected transmitting parent
    is common and a negative family history does not exclude the diagnosis.
  evidence:
  - reference: PMID:19182804
    reference_title: "Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report the discovery of a mutation in the THAP1 gene in three Amish-Mennonite families with mixed-onset primary torsion dystonia (also known as DYT6 dystonia)."
    explanation: >-
      The original family-based identification of THAP1 as the DYT6 locus.
  - reference: PMID:21793105
    reference_title: "DYT6 dystonia: review of the literature and creation of the UMD Locus-Specific Database (LSDB) for mutations in the THAP1 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "account for a substantial proportion of familial, early-onset, nonfocal, primary dystonia cases"
    explanation: >-
      Confirms familial transmission across many independent reports.
pathophysiology:
- name: Heterozygous THAP1 Loss-of-Function Variants
  biological_scale: MOLECULAR
  description: >-
    Heterozygous variants in THAP1, most often missense changes affecting the
    N-terminal THAP DNA-binding domain, but also frameshift and nonsense alleles.
    More than eighty variants have been reported and about two thirds are
    missense. Different variant classes reach the same endpoint by different
    routes: some abolish DNA binding, some destabilise the protein, and some leave
    DNA binding intact while abolishing cofactor recruitment.
  genetic_context:
    variant_origin: GERMLINE
    functional_impact_category: LOSS_OF_FUNCTION
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Reduced THAP1 Transcriptional Regulatory Function
    description: >-
      Loss of DNA binding, loss of protein stability, or loss of cofactor
      recruitment each reduce the amount of functional THAP1 regulatory activity
      at target promoters.
  evidence:
  - reference: PMID:32112337
    reference_title: "Unraveling Molecular Mechanisms of THAP1 Missense Mutations in DYT6 Dystonia."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: "Until now, more than eighty different mutations in THAP1 gene have been found in patients with primary dystonia, and two third of them are missense mutations."
    explanation: >-
      Quantifies the variant spectrum and the predominance of missense change.
      Graded IN_VITRO because evidence_source classifies the publication, and this
      publication is a cell-based study: SK-N-AS and HEK293 transfection, patient
      fibroblast immunoblot, microarray, ChIP-seq and promoter luciferase assays.
      Cached MeSH is Cell Line Tumor, Cells Cultured, HEK293 Cells, Fibroblasts and
      Neurons. Marked INDIRECT because the quoted sentence is the paper's own
      introduction summarising the published mutation spectrum rather than a result
      it measures. The same PMID is graded IN_VITRO at four other sites in this file.
  - reference: PMID:19182804
    reference_title: "Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We demonstrate that the missense mutation impairs DNA binding, suggesting that transcriptional dysregulation may contribute to the phenotype of DYT6 dystonia."
    explanation: >-
      Shows the functional consequence of a disease missense variant on DNA
      binding. Graded IN_VITRO because the DNA-binding demonstration is a
      biochemical assay, while the family identification in the same paper is
      clinical.
- name: Reduced THAP1 Transcriptional Regulatory Function
  biological_scale: MOLECULAR
  description: >-
    The convergence point of the variant classes. THAP1 is a zinc-finger
    transcription factor, and disease variants reduce its regulatory output either
    by impairing sequence-specific DNA binding, by reducing protein stability and
    so effective dosage, or by abolishing recruitment of the HCFC1 cofactor at
    promoters THAP1 still binds. The last of these is the reason a variant can be
    pathogenic with normal DNA binding.
  molecular_functions:
  - preferred_term: sequence-specific DNA binding by the THAP zinc-finger domain
    modifier: DECREASED
    term:
      id: GO:0043565
      label: sequence-specific DNA binding
  downstream:
  - target: Transcriptional Dysregulation Through the SP1 Family
    description: >-
      Reduced THAP1 regulatory function propagates into a much wider expression
      change than its own direct target set, because it acts through other
      transcription factors.
  - target: Derepression of TOR1A
    description: >-
      THAP1's best-characterised direct target. Wild-type THAP1 represses the
      TOR1A promoter, so reduced THAP1 function releases that repression. This is
      the specific, measured arm of the transcriptional lesion, as distinct from
      the broad SP1-mediated arm above.
  evidence:
  - reference: PMID:28486698
    reference_title: "Dystonia-causing mutations in the transcription factor THAP1 disrupt HCFC1 cofactor recruitment and alter gene expression."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We investigated the consequences of these mutations on the interaction of THAP1 with HCFC1 and demonstrated that all three mutations abolished HCFC1-THAP1 complex formation."
    explanation: >-
      Shows a distinct loss-of-function route: three patient variants in the
      HCFC1-binding motif abolish cofactor recruitment.
  - reference: PMID:28486698
    reference_title: "Dystonia-causing mutations in the transcription factor THAP1 disrupt HCFC1 cofactor recruitment and alter gene expression."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: "Quantitative ChIP on selected promoters revealed that none of the mutations significantly decreased the DNA-binding ability of THAP1 while HCFC1 binding was highly reduced."
    explanation: >-
      Establishes that this route is independent of DNA binding. Marked INDIRECT
      because it supports the node by excluding the alternative mechanism rather
      than by measuring regulatory output directly.
  - reference: PMID:32112337
    reference_title: "Unraveling Molecular Mechanisms of THAP1 Missense Mutations in DYT6 Dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In addition, we show that some THAP1 mutations (C54Y and F81L) decrease the protein stability which might also be responsible for altered transcription regulation due to dosage insufficiency."
    explanation: >-
      Documents the protein-stability route to reduced regulatory function.
- name: Derepression of TOR1A
  biological_scale: MOLECULAR
  description: >-
    THAP1 binds the core promoter of TOR1A and represses it; DYT6-associated
    mutant THAP1 represses it less. TOR1A is the gene mutated in DYT1 dystonia, so
    this is the molecular link between the two commonest monogenic isolated
    dystonias, and it is the reason a transcription-factor disease and a
    torsinA-protein disease can converge on one clinical syndrome.

    Recorded as a distinct node rather than folded into the SP1 arm because the
    binding is direct and demonstrated by promoter assay and ChIP, whereas the SP1
    arm is an indirect expression-level effect. No downstream edge is asserted from
    here: how much of the dystonia is attributable to TOR1A derepression rather
    than to the wider expression change is not established by the curated evidence.
  molecular_functions:
  - preferred_term: repression of the TOR1A core promoter by THAP1
    modifier: DECREASED
    term:
      id: GO:0000976
      label: transcription cis-regulatory region binding
  evidence:
  - reference: PMID:20976771
    reference_title: "The dystonia gene DYT1 is repressed by the transcription factor THAP1 (DYT6)."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Further, we report that wild type THAP1 represses the expression of TOR1A, whereas dystonia 6-associated mutant THAP1 results in decreased repression of TOR1A."
    explanation: >-
      States both the normal repressive function and the direction of its loss in
      disease-associated mutants, which is the whole claim of this node.
  - reference: PMID:20865765
    reference_title: "Direct interaction between causative genes of DYT1 and DYT6 primary dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using electromobility shift assays and chromatin immunoprecipitation (ChIP) quantitative polymerase chain reaction (qPCR), we demonstrate a physical interaction between THAP1 and the TOR1A promoter that is abolished by pathophysiologic mutations."
    explanation: >-
      Independent demonstration of the physical interaction and its loss, by two
      methods, which is what makes this a direct target rather than a correlated
      expression change.
- name: Transcriptional Dysregulation Through the SP1 Family
  biological_scale: MOLECULAR
  description: >-
    THAP1 turns out to account directly for only a minority of the genes that
    change when it is mutated. The bulk of the effect runs through the SP1 family
    transcription factors SP1 and SP4, and it is cell-type dependent - which is a
    plausible part of why a ubiquitously expressed transcription factor produces a
    disorder confined to motor control.
  biological_processes:
  - preferred_term: regulation of transcription by RNA polymerase II
    modifier: DYSREGULATED
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
  downstream:
  - target: Reduced Striatal GABAergic Transmission
    description: >-
      Among the dysregulated gene sets are those governing synaptic transmission,
      and the measured consequence in patient-derived striatal neurons is a
      GABAergic deficit.
  - target: Basal Ganglia and Cerebellar Motor Network Dysfunction
    description: >-
      Transcriptional changes affecting nervous system development and synaptic
      transmission are the proposed origin of the circuit-level abnormality.
      Supported in rodent models rather than demonstrated in humans.
  evidence:
  - reference: PMID:35015830
    reference_title: "DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "THAP1 mutations lead to dysregulation of genes mainly through regulation of SP1 family members, SP1 and SP4, in a cell type dependent manner."
    explanation: >-
      States the SP1/SP4 route and its cell-type dependence, which is the core
      claim of this node.
  - reference: PMID:35015830
    reference_title: "DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We observed that THAP1 targeted only a minority of differentially expressed genes caused by its mutation."
    explanation: >-
      Supports the claim that most of the expression change is indirect rather
      than at THAP1's own binding sites.
  - reference: PMID:32112337
    reference_title: "Unraveling Molecular Mechanisms of THAP1 Missense Mutations in DYT6 Dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ChIP-seq showed that THAP1 can bind to the promoter of one of these genes, superoxide dismutase 2 (SOD2)."
    explanation: >-
      An example of a directly bound target gene, complementing the indirect
      SP1-family route.
- name: Reduced Striatal GABAergic Transmission
  biological_scale: CELLULAR
  description: >-
    The most concrete cellular defect demonstrated in human cells. Patient-derived
    striatal medium spiny neurons show downregulation of the GABA-A receptor alpha2
    subunit, lower calcium responses to GABA, and reduced miniature postsynaptic
    current frequency, with an increased rate of spontaneous action potentials -
    that is, disinhibition and hyperexcitability.
  biological_processes:
  - preferred_term: synaptic transmission, GABAergic
    modifier: DECREASED
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
  cell_types:
  - preferred_term: striatal medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  downstream:
  - target: Basal Ganglia and Cerebellar Motor Network Dysfunction
    description: >-
      Disinhibited, hyperexcitable striatal projection neurons are the proposed
      cellular substrate of abnormal basal ganglia output.
  evidence:
  - reference: PMID:34095114
    reference_title: "Reduced Expression of GABA (A) Receptor Alpha2 Subunit Is Associated With Disinhibition of DYT-THAP1 Dystonia Patient-Derived Striatal Medium Spiny Neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Calcium imaging and quantitative PCR analysis revealed significantly lower Ca2+ amplitudes upon GABA applications and a marked downregulation of the gene encoding the GABA A receptor alpha2 subunit in THAP1 MSNs indicating a decreased GABAergic transmission."
    explanation: >-
      Measures the GABAergic deficit in patient-derived neurons, which is the
      claim of this node.
  - reference: PMID:34095114
    reference_title: "Reduced Expression of GABA (A) Receptor Alpha2 Subunit Is Associated With Disinhibition of DYT-THAP1 Dystonia Patient-Derived Striatal Medium Spiny Neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Whole-cell patch-clamp recordings showed a significantly lower frequency of miniature postsynaptic currents (mPSCs), whereas the frequency of spontaneous action potentials (APs) was elevated in THAP1 MSNs suggesting that decreased synaptic activity might have resulted in enhanced generation of APs."
    explanation: >-
      Documents the electrophysiological disinhibition and hyperexcitability
      described in this node.
- name: Basal Ganglia and Cerebellar Motor Network Dysfunction
  biological_scale: TISSUE
  description: >-
    The least resolved step, and the entry says so. Abnormal output from basal
    ganglia-thalamo-cortical loops, with a parallel cerebellar contribution, is
    the standard account of how a striatal cellular defect becomes dystonic
    movement. The human evidence is structural imaging showing damaged axonal
    integrity in sensorimotor white matter; the circuit-level causal account comes
    from rodent models, which do not reproduce the human phenotype. No human study
    curated here demonstrates the causal step from this node to dystonia.
  locations:
  - preferred_term: basal ganglion
    term:
      id: UBERON:0002420
      label: basal ganglion
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  downstream:
  - target: Isolated Dystonia
    description: >-
      Aberrant sensorimotor integration and loss of surround inhibition are the
      proposed proximate cause of the dystonic posture and movement. This edge is
      inferred rather than demonstrated.
  evidence:
  - reference: PMID:22652465
    reference_title: "Subcellular distribution of THAP1 and alterations in the microstructure of brain white matter in DYT6 dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The axonal integrity and coherence in the region of sensorimotor area of the brain was damaged in DYT6 dystonia."
    explanation: >-
      Human diffusion tensor imaging evidence of a sensorimotor white-matter
      abnormality in genotyped patients. Note that the same abstract's results
      sentence attributes the fractional anisotropy reduction to "DYT1 carriers"
      while the study enrolled DYT6 patients; the conclusion sentence quoted here
      is the unambiguous statement and is used for that reason.
  - reference: PMID:30590536
    reference_title: "Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "Although these mice do not exhibit dystonia, they show pronounced locomotor deficits reflecting derangements in the cerebellar and basal ganglia circuitry."
    explanation: >-
      Supports involvement of cerebellar and basal ganglia circuitry, and is
      marked INDIRECT for the strongest possible reason: the same sentence records
      that the model does not produce dystonia, so it bears on the circuit claim
      without bearing on the step to the clinical phenotype.
- name: Isolated Dystonia
  biological_scale: ORGANISM
  description: >-
    The clinical endpoint: sustained or intermittent involuntary muscle
    contractions producing abnormal postures and repetitive movements, with no
    other neurological sign. Onset is typically in childhood or adolescence, most
    often craniocervical or laryngeal, with spread to the limbs. Penetrance is
    incomplete, so this node is reached by only a fraction of carriers.
  downstream:
  - target: Torticollis
  - target: Laryngeal dystonia
  - target: Dysarthria
  - target: Writer's cramp
  - target: Oromandibular dystonia
  - target: Blepharospasm
  - target: Generalized dystonia
  evidence:
  - reference: PMID:20825472
    reference_title: "Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Whilst in the DYT6 cases, the onset was cranial or cervical and progresses very slowly."
    explanation: >-
      Describes the characteristic onset distribution and tempo that distinguish
      this entity from DYT1 dystonia.
  - reference: PMID:21793105
    reference_title: "DYT6 dystonia: review of the literature and creation of the UMD Locus-Specific Database (LSDB) for mutations in the THAP1 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Therefore, we carried out a systematic review of the literature on the THAP1 gene to colligate all reported patients with a specific THAP1 mutation and the associated clinical signs in order to describe the broad phenotypic continuum of this disorder."
    explanation: >-
      Establishes that the clinical picture is a continuum rather than a single
      stereotyped presentation.
phenotypes:
- category: Neurologic
  name: Torticollis
  description: >-
    Cervical dystonia. The neck is the most frequently affected region, and
    cervical onset is one of the two characteristic presentations.
  phenotype_term:
    preferred_term: Cervical dystonia
    term:
      id: HP:0000473
      label: Torticollis
  evidence:
  - reference: PMID:20825472
    reference_title: "Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Whilst in the DYT6 cases, the onset was cranial or cervical and progresses very slowly."
    explanation: >-
      Reports cervical onset as one of the characteristic presentations.
- category: Neurologic
  name: Laryngeal dystonia
  description: >-
    Spasmodic dysphonia. Laryngeal involvement is a recognised and relatively
    distinctive feature of this entity within the isolated dystonias.
  phenotype_term:
    preferred_term: Spasmodic dysphonia
    term:
      id: HP:0012049
      label: Laryngeal dystonia
  evidence:
  - reference: PMID:21793105
    reference_title: "DYT6 dystonia: review of the literature and creation of the UMD Locus-Specific Database (LSDB) for mutations in the THAP1 gene."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The identification of a larger number of THAP1 mutations and collection of high-quality clinical information for each described mutation through international collaborative effort will help investigating the structure-function and genotype-phenotype correlations in DYT6 dystonia."
    explanation: >-
      Marked INDIRECT and worth reading as such. The systematic review this quote
      comes from is the entry's source for the phenotypic continuum that includes
      laryngeal involvement, but the abstract does not enumerate the individual
      body regions, so no quote in the cached record asserts laryngeal dystonia
      directly. Recorded honestly rather than supported by a quote that does not
      say it.
- category: Neurologic
  name: Dysarthria
  description: >-
    Speech impairment arising from cranial and laryngeal dystonia rather than from
    a corticobulbar lesion.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:20825472
    reference_title: "Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "CONCLUSION: The major clinical differences between DYT1 and DYT6 dystonia in China were the cranial involvement in DYT6 and progress to general dystonia within several years in DYT1."
    explanation: >-
      Supports cranial involvement, of which dysarthria is a manifestation.
      Marked INDIRECT because the quote names the region rather than the symptom.
- category: Neurologic
  name: Writer's cramp
  description: >-
    Task-specific focal dystonia of the upper limb, part of the brachial
    involvement characteristic of spread in this disorder.
  phenotype_term:
    preferred_term: Task-specific upper limb dystonia
    term:
      id: HP:0002356
      label: Writer's cramp
  evidence:
  - reference: PMID:21793105
    reference_title: "DYT6 dystonia: review of the literature and creation of the UMD Locus-Specific Database (LSDB) for mutations in the THAP1 gene."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Currently, 56 families present with a THAP1 mutation; however, no genotype/phenotype relationship has been found."
    explanation: >-
      Marked INDIRECT for the same reason as laryngeal dystonia: the cached
      abstract establishes a broad phenotypic continuum across 56 families
      without enumerating body regions. The region is clinically well described
      but is not asserted by any quote available in this entry's reference cache.
- category: Neurologic
  name: Oromandibular dystonia
  description: >-
    Dystonia of the jaw, tongue and lower face, part of the cranial involvement
    that distinguishes this entity from DYT1 dystonia.
  phenotype_term:
    preferred_term: Oromandibular dystonia
    term:
      id: HP:0012048
      label: Oromandibular dystonia
  evidence:
  - reference: PMID:20825472
    reference_title: "Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major clinical differences between DYT1 and DYT6 dystonia in China were the cranial involvement in DYT6"
    explanation: >-
      Supports cranial involvement, of which oromandibular dystonia is a
      manifestation. Marked INDIRECT because the quote names the region rather
      than the specific pattern.
- category: Neurologic
  name: Blepharospasm
  description: >-
    Involuntary forced eyelid closure, a cranial dystonia manifestation.
  phenotype_term:
    preferred_term: Blepharospasm
    term:
      id: HP:0000643
      label: Blepharospasm
  evidence:
  - reference: PMID:20825472
    reference_title: "Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "the cranial involvement in DYT6"
    explanation: >-
      Supports cranial involvement, of which blepharospasm is a manifestation.
      Marked INDIRECT because the quote names the region rather than the sign.
- category: Neurologic
  name: Generalized dystonia
  description: >-
    Spread from a focal onset to segmental and then generalized distribution. This
    is described as slower in this disorder than in DYT1 dystonia, which
    generalizes within a few years.
  phenotype_term:
    preferred_term: Generalized dystonia
    term:
      id: HP:0007325
      label: Generalized dystonia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20825472
    reference_title: "Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical presentations of the DYT1 cases included onset in the limbs that could progress to the generalized dystonia within several years but without cranial involvement."
    explanation: >-
      Establishes the contrasting DYT1 tempo against which this disorder's slower
      spread is described in the same study.
genetic:
- name: THAP1
  gene_term:
    preferred_term: THAP1
    term:
      id: hgnc:20856
      label: THAP1
  relationship_type: CAUSATIVE
  case_fractions:
  - population: Unselected Chinese primary dystonia cohort
    case_fraction_percent: 1.8
    notes: >-
      THAP1 share of an unselected primary dystonia cohort, alongside TOR1A at
      2.7 percent for a combined 4.5 percent. The small share is why common
      sporadic focal disease is curated separately in Cervical_Dystonia with
      THAP1 typed SUSCEPTIBILITY rather than CAUSATIVE.
    evidence:
    - reference: PMID:20825472
      reference_title: "Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The overall mutation frequency was 4.5% in this cohort with TOR1A mutations found in 2.7% and THAP1 mutations found in 1.8%."
      explanation: >-
        Source for the 1.8 percent THAP1 share and the 4.5 percent combined
        figure.
  notes: >-
    THAP1 is hgnc:20856. It is not THAP11, which is hgnc:23194 and causes an
    unrelated disorder; the two have been confused in at least one deep-research
    output, and the confusion is not caught by term validation because a CURIE and
    its label can agree while naming a gene the surrounding text does not (see
    dismech issue #10948). The binding here was read from the HGNC term cache.

    More than eighty pathogenic variants are known, about two thirds missense.
    Whether they correlate with phenotype is disputed: the 2011 LSDB review of 56
    families found no relationship, while a later screen of over 1800 subjects
    found that truncating and THAP-domain missense variants manifest earlier and
    involve more body regions. Both are cited below. This entry makes no
    variant-specific severity claim of its own, not because the question is
    settled in the negative but because it is open.
  evidence:
  - reference: PMID:21793105
    reference_title: "DYT6 dystonia: review of the literature and creation of the UMD Locus-Specific Database (LSDB) for mutations in the THAP1 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "THAP1 is the first transcriptional factor involved in primary dystonia and the hypothesis of a transcriptional deregulation, which was primarily proposed for the X-linked dystonia-parkinsonism (DYT3 dystonia), provided thus a new way to investigate the possible mechanism underlying the development of dystonic movements."
    explanation: >-
      Establishes THAP1's identity as a transcription factor and the significance
      of that for the mechanism.
  - reference: PMID:21793105
    reference_title: "DYT6 dystonia: review of the literature and creation of the UMD Locus-Specific Database (LSDB) for mutations in the THAP1 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Currently, 56 families present with a THAP1 mutation; however, no genotype/phenotype relationship has been found."
    explanation: >-
      States the absence of genotype-phenotype correlation recorded in the notes.
  - reference: PMID:22377579
    reference_title: "Genotype-phenotype correlations in THAP1 dystonia: molecular foundations and description of new cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Protein truncating mutations and missense mutations within the THAP domain of THAP1 tend to manifest at an earlier age and exhibit more extensive anatomical distributions than mutations localized to other regions of THAP1."
    explanation: >-
      Reports a variant-class effect on onset age and anatomical spread across
      more than 1800 subjects, which supports the THAP1 gene-disease relationship
      this record asserts. That it disagrees with the 2011 review quoted above is
      a disagreement between two sources, recorded in this record's notes and in
      the dyt6_no_genotype_phenotype_correlation discussion rather than by
      grading this item against a sibling item.
  - reference: PMID:22377579
    reference_title: "Genotype-phenotype correlations in THAP1 dystonia: molecular foundations and description of new cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mean age of onset for THAP1 dystonia is 16.8 years and the most common sites of onset are the arm and neck, and the most frequently affected anatomical site is the neck."
    explanation: >-
      Quantifies onset age and the commonest sites, which the entry previously
      described only qualitatively.
  - reference: PMID:39732371
    reference_title: "Peripheral nerve injury induces dystonia-like movements and dysregulation in the energy metabolism: A multi-omics descriptive study in Thap1(+/-) mice."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "The incomplete penetrance of DYT-THAP1 dystonia, estimated at 40 to 60 %, suggests that an environmental trigger may be required for the manifestation of the disease in genetically predisposed individuals."
    explanation: >-
      Puts a number on the incomplete penetrance the entry relies on, and states
      the environmental-trigger hypothesis the knowledge gap below turns on.
      Graded MODEL_ORGANISM because evidence_source classifies the publication,
      and this one is a Thap1(+/-) mouse multi-omics study; its MeSH terms are
      Animals, Mice, Mice Knockout and Disease Models Animal. Marked INDIRECT
      because the quoted sentence is the paper's own background statement of a
      human figure rather than a result it measures. Citing the primary human
      penetrance source would be better and is not done here.
animal_models:
- name: Thap1 heterozygous knockout mouse
  species: Mouse
  genotype: Thap1 heterozygous null
  publication: PMID:30590536
  description: >-
    The genotype that should, in principle, model human THAP1 haploinsufficiency.
    Unprovoked, it does not: the mouse compensates by upregulating transcription
    from the intact allele and has no discernable phenotype. Given a second hit it
    does. After sciatic nerve crush, Thap1+/- mice show significantly more
    dystonia-like movements than naive Thap1+/- mice and than injured wild-type
    mice, so the genotype carries a real susceptibility that is invisible without
    a trigger. Both results are modelled below, as separate links, because they
    are claims about different nodes.
  modeled_mechanisms:
  - target: Reduced THAP1 Transcriptional Regulatory Function
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    model_scale: MOLECULAR
    description: >-
      The model fails at the first node it is meant to reproduce: transcriptional
      autoregulation restores Thap1 message, so the haploinsufficient state the
      human disease depends on is not established.
    limitations: >-
      Thap1 mRNA is autoregulated in mouse, with upregulation at the non-affected
      locus, so heterozygous deletion does not produce a reduced-dosage state.
      Germline homozygous deletion cannot be used instead because it is embryonic
      lethal. The failure is a species difference in gene dosage compensation, not
      a limitation of the construct. This grading is about the molecular node only:
      the same animal does produce a dystonic phenotype after a peripheral nerve
      injury, which is recorded as a separate link below. Read together, the model
      is uninformative about steady-state THAP1 dosage and informative about
      gene-environment interaction.
    divergences:
    - divergence_type: SPECIES_MISMATCH
      materiality: INVALIDATING
      description: >-
        Mouse compensates for the loss of one Thap1 allele by upregulating the
        remaining one. No comparable autoregulatory rescue is described in human
        carriers, who are symptomatic at the same genotype.
    evidence:
    - reference: PMID:30590536
      reference_title: "Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes."
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: "While germ-line deletion of Thap1 is embryonic lethal, mice lacking one Thap1 allele-which in principle should recapitulate the haploinsufficiency of the human syndrome-do not show a discernable phenotype."
      explanation: >-
        The authors' own statement that the model does not reproduce the human
        haploinsufficient state.
    - reference: PMID:30590536
      reference_title: "Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "This is because mice show autoregulation of Thap1 mRNA levels with upregulation at the non-affected locus."
      explanation: >-
        Gives the mechanism of the failure, which is what makes this a species
        mismatch rather than an unexplained negative result.
  - target: Isolated Dystonia
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    description: >-
      After a peripheral nerve crush, the heterozygote produces dystonia-like
      movements exceeding both naive heterozygotes and injured wild-type animals.
      The genotype supplies the predisposition and the injury supplies the
      trigger, which is a two-hit model of the incomplete penetrance seen in human
      carriers.
    limitations: >-
      The trigger is an experimental sciatic nerve crush, not an exposure reported
      in human DYT6, so the gene-environment interaction is demonstrated in
      principle rather than as the human mechanism. The readout is an automated
      movement classification rather than a clinical dystonia diagnosis, and the
      multi-omic differences reported alongside it are descriptive and not shown
      to be causal.
    divergences:
    - divergence_type: SPECIES_MISMATCH
      materiality: QUALIFYING
      description: >-
        A peripheral nerve injury is not a recognised precipitant of human THAP1
        dystonia. The claim this link supports is that a second hit can unmask the
        genotype, not that this particular second hit is the human one.
    evidence:
    - reference: PMID:39732371
      reference_title: "Peripheral nerve injury induces dystonia-like movements and dysregulation in the energy metabolism: A multi-omics descriptive study in Thap1(+/-) mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Phenotypic analysis using an unbiased deep learning algorithm revealed that nerve-injured Thap1+/- mice exhibited significantly more dystonia like movements (DLM) over the course of the 12-week experiment compared to naive Thap1+/- mice."
      explanation: >-
        The genotype-dependent effect of the second hit, which is what licenses
        PARTIALLY_RECAPITULATES against the dystonia node.
    - reference: PMID:39732371
      reference_title: "Peripheral nerve injury induces dystonia-like movements and dysregulation in the energy metabolism: A multi-omics descriptive study in Thap1(+/-) mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Furthermore, at week 11 after nerve crush, nerve-injured Thap1+/- mice displayed significantly more DLM than nerve-injured wt counterparts."
      explanation: >-
        Separates the genotype effect from the effect of injury alone, which is
        the comparison that makes this a gene-environment result rather than a
        nerve-injury result.
  evidence:
  - reference: PMID:30590536
    reference_title: "Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: "mice lacking one Thap1 allele-which in principle should recapitulate the haploinsufficiency of the human syndrome-do not show a discernable phenotype"
    explanation: >-
      Attests that this model is not informative for the human disease at the
      genotype that matches it.
- name: Nestin-conditional Thap1 knockout mouse
  species: Mouse
  genotype: Thap1 conditional deletion in nestin-expressing glial and neuronal precursors
  publication: PMID:30590536
  description: >-
    Deletion of Thap1 in neural precursors, used to get past the embryonic
    lethality of germline deletion and the autoregulatory rescue in heterozygotes.
    It produces locomotor deficits and transcriptional changes overlapping other
    dystonic syndromes, but still no dystonia.
  modeled_mechanisms:
  - target: Basal Ganglia and Cerebellar Motor Network Dysfunction
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    description: >-
      Reproduces circuit-level derangement in the cerebellar and basal ganglia
      pathways, and the transcriptional signature, without reproducing the
      disease's defining motor phenotype.
    limitations: >-
      The model does not develop dystonia. Deletion is in neural precursors rather
      than a heterozygous point variant, so the genetic lesion is more severe and
      earlier than the human one, and the readout is locomotor deficit rather than
      dystonic posturing.
    divergences:
    - divergence_type: OTHER
      materiality: QUALIFYING
      description: >-
        The model reaches the circuit node but not the clinical endpoint:
        locomotor deficits are observed, while sustained involuntary muscle
        contraction producing abnormal posture, which is what defines dystonia,
        is not. Typed OTHER because ModelDivergenceTypeEnum has no value for a
        model that reproduces the mechanism but not the phenotype; the nearest
        candidate discussed in CLAUDE.md, INCOMPLETE_PHENOTYPE, is named there as
        a likely future addition and is not currently a permissible value.
    evidence:
    - reference: PMID:30590536
      reference_title: "Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Although these mice do not exhibit dystonia, they show pronounced locomotor deficits reflecting derangements in the cerebellar and basal ganglia circuitry."
      explanation: >-
        States both the circuit finding this link records and the phenotypic
        limitation that caps its fidelity.
  evidence:
  - reference: PMID:30590536
    reference_title: "Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These behavioral features are associated with alterations in the expression of genes involved in nervous system development, synaptic transmission, cytoskeleton, gliosis and dopamine signaling that link DYT6 to other primary and secondary dystonic syndromes."
    explanation: >-
      Supports treating the model as informative for the transcriptional and
      circuit nodes, through the pathway overlap with other dystonic syndromes.
experimental_models:
- name: Patient-derived iPSC striatal medium spiny neurons
  experimental_model_type: IPSC_DERIVED_MODEL
  publication: PMID:34095114
  description: >-
    Medium spiny neurons differentiated from induced pluripotent stem cells of two
    THAP1 patients and one reduced-penetrance family member, compared with healthy
    controls. This is the human model that succeeds where the mouse fails, because
    it carries the patient genotype in human cells.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_types:
  - preferred_term: striatal medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  modeled_mechanisms:
  - target: Reduced Striatal GABAergic Transmission
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Directly measures the GABAergic deficit in the cell type and species the
      node is about.
    limitations: >-
      Derived from three individuals carrying two variants, so the finding is not
      established across the allelic spectrum. iPSC-derived neurons are
      developmentally immature relative to adult striatum, and the culture lacks
      the afferent and efferent connectivity in which the circuit-level claim
      would have to be tested.
    readouts:
    - name: GABA-A receptor alpha2 subunit expression
      target: Reduced Striatal GABAergic Transmission
      direction: DECREASED
      interpretation: >-
        Transcript-level correlate of the reduced GABAergic transmission at this
        node.
      evidence:
      - reference: PMID:34095114
        reference_title: "Reduced Expression of GABA (A) Receptor Alpha2 Subunit Is Associated With Disinhibition of DYT-THAP1 Dystonia Patient-Derived Striatal Medium Spiny Neurons."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "a marked downregulation of the gene encoding the GABA A receptor alpha2 subunit in THAP1 MSNs"
        explanation: >-
          Reports the direction and target of this measurement.
    - name: Miniature postsynaptic current frequency
      target: Reduced Striatal GABAergic Transmission
      direction: DECREASED
      interpretation: >-
        Electrophysiological correlate of reduced synaptic transmission.
      evidence:
      - reference: PMID:34095114
        reference_title: "Reduced Expression of GABA (A) Receptor Alpha2 Subunit Is Associated With Disinhibition of DYT-THAP1 Dystonia Patient-Derived Striatal Medium Spiny Neurons."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Whole-cell patch-clamp recordings showed a significantly lower frequency of miniature postsynaptic currents (mPSCs)"
        explanation: >-
          Reports the direction of this measurement.
    - name: Spontaneous action potential frequency
      target: Reduced Striatal GABAergic Transmission
      direction: INCREASED
      interpretation: >-
        Hyperexcitability resulting from loss of inhibitory input.
      evidence:
      - reference: PMID:34095114
        reference_title: "Reduced Expression of GABA (A) Receptor Alpha2 Subunit Is Associated With Disinhibition of DYT-THAP1 Dystonia Patient-Derived Striatal Medium Spiny Neurons."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "whereas the frequency of spontaneous action potentials (APs) was elevated in THAP1 MSNs"
        explanation: >-
          Reports the direction of this measurement.
    evidence:
    - reference: PMID:34095114
      reference_title: "Reduced Expression of GABA (A) Receptor Alpha2 Subunit Is Associated With Disinhibition of DYT-THAP1 Dystonia Patient-Derived Striatal Medium Spiny Neurons."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "induced pluripotent stem cell (iPSC)-derived medium spiny neurons (MSNs) from two patients and one family member with reduced penetrance carrying a mutation in the gene THAP1"
      explanation: >-
        Establishes the model's construction and that it carries patient
        genotypes, which is why it is treated as informative for this node.
- name: THAP1 mutant stable neuronal cell lines
  experimental_model_type: CELL_LINE
  publication: PMID:32112337
  description: >-
    SK-N-AS neuroblastoma lines stably expressing wild-type or patient-derived
    mutant THAP1, used for transcriptional profiling and protein stability
    testing.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  modeled_mechanisms:
  - target: Reduced THAP1 Transcriptional Regulatory Function
    relationship: MEASURES
    fidelity: MODERATE
    model_scale: MOLECULAR
    description: >-
      Measures the transcriptional and protein-stability consequences of
      individual patient missense variants.
    limitations: >-
      An overexpression system in a neuroblastoma line, so the dosage is not
      physiological and the cell type is not a striatal projection neuron. Two
      variants were profiled, so the shared 28-gene signature is not established
      across the allelic spectrum.
    evidence:
    - reference: PMID:32112337
      reference_title: "Unraveling Molecular Mechanisms of THAP1 Missense Mutations in DYT6 Dystonia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Transcriptional profiling using microarrays revealed a set of 28 common genes dysregulated in two mutated THAP1 (S21T and F81L) overexpression cell lines suggesting a common mechanism of these mutations."
      explanation: >-
        Reports the shared dysregulated gene set this model contributes.
treatments:
- name: Oral pharmacotherapy
  description: >-
    The first tier of the dystonia treatment algorithm, used before chemodenervation
    and surgery: anticholinergics, baclofen and clonazepam, all off-label. A
    levodopa trial is standard in young-onset dystonia to exclude dopa-responsive
    dystonia, which is a different disease rather than a treatment for this one.
    Like everything else here it is symptomatic and does nothing about the
    transcriptional lesion.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: oral pharmacotherapy for dystonia
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Isolated Dystonia
    description: >-
      Acts on the motor endpoint by modulating cholinergic and GABAergic tone,
      downstream of every mechanistic node in this entry.
  notes: >-
    therapeutic_agent is left absent deliberately. The cited source names the drug
    classes rather than reporting an outcome for any one agent in THAP1-genotyped
    patients, so binding a specific CHEBI agent would assert more than the evidence
    carries.
  evidence:
  - reference: PMID:31117876
    reference_title: "Update on current and emerging therapies for dystonia."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Oral anticholinergics, baclofen and clonazepam are used off-label, but novel drugs in development include sodium oxybate, zonisamide and perampanel."
    explanation: >-
      Names the first-tier oral agents and records that their use is off-label.
      INDIRECT because the source is a dystonia-management review rather than a
      THAP1-genotyped study.
- name: Botulinum toxin chemodenervation
  description: >-
    Intramuscular botulinum toxin injection into the dystonic muscles, the
    standard symptomatic treatment for focal and segmental dystonia. It acts on
    the effector end of the chain and does nothing about the transcriptional
    lesion.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: botulinum toxin chemodenervation
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Isolated Dystonia
    description: >-
      Blocks acetylcholine release at the neuromuscular junction of the injected
      muscle, reducing the dystonic contraction. Symptomatic only, and downstream
      of every mechanistic node in this entry.
  notes: >-
    therapeutic_modality is OTHER, not SMALL_MOLECULE. Botulinum neurotoxin is a
    roughly 150 kDa bacterial protein, so SMALL_MOLECULE is factually wrong, and
    PEPTIDE would be almost as wrong at that size. PROTEIN_REPLACEMENT does not
    apply because nothing deficient is being replaced. OTHER is the honest
    remainder. Note the KB is inconsistent here: botulinum treatments elsewhere
    carry SMALL_MOLECULE about as often as OTHER, which is worth a sweep.

    therapeutic_agent is left absent. NCIT:C163032 Botulinum Toxin and
    NCIT:C82623 Botulinum Toxin Type A both exist and were read from the NCIT
    cache, but the evidence below is a dystonia-management guideline rather than a
    THAP1-genotyped series, so the agent is named in the description rather than
    bound as an evidence-backed claim about this disorder specifically. The
    openscientist report offered NCIT:C1084 for botulinum toxin; that CURIE is
    Staphylococcal Enterotoxin B, and it was not used.
  evidence:
  - reference: PMID:31117876
    reference_title: "Update on current and emerging therapies for dystonia."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chemodenervation with botulinum toxin remains the treatment of choice for focal- or select-body regions in generalized and segmental dystonia."
    explanation: >-
      Establishes botulinum toxin as first-line for the focal and segmental
      distribution this disorder presents with. Marked INDIRECT because the source
      is a dystonia-management review and does not report a THAP1-genotyped
      cohort, so it supports the practice rather than an outcome in DYT6.
- name: Deep brain stimulation of the globus pallidus internus
  description: >-
    Bilateral pallidal deep brain stimulation, used for medically refractory
    generalized or segmental dystonia. It intervenes at the network node rather
    than at the muscle, which makes it the one treatment in this entry that acts
    inside the pathograph rather than at its endpoint.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: deep brain stimulation
    term:
      id: NCIT:C21024
      label: Deep Brain Stimulation
  target_mechanisms:
  - target: Basal Ganglia and Cerebellar Motor Network Dysfunction
    description: >-
      Modulates pallidal output, altering the abnormal basal ganglia-thalamo-cortical
      signalling proposed to generate the dystonia.
  notes: >-
    The openscientist report for this disease offered NCIT:C38150 for deep brain
    stimulation; that CURIE is PEComa, and it was not used. The term bound here,
    NCIT:C21024, was read from the NCIT term cache.
  evidence:
  - reference: PMID:31817799
    reference_title: "Pallidal Deep Brain Stimulation in DYT6 Dystonia: Clinical Outcome and Predictive Factors for Motor Improvement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All benefited from surgery: dystonia severity was reduced by a median of 58% (IQR 31-62, p = 0.001) at last follow-up, as assessed by the Burke Fahn Marsden movement subscale."
    explanation: >-
      Reports the outcome in a genotyped THAP1 cohort, which is what makes this
      evidence about this disorder rather than about dystonia generally.
  - reference: PMID:21949105
    reference_title: "Pallidal deep brain stimulation for DYT6 dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DYT6 patients appear to respond less robustly to GPi-DBS than their DYT1 counterparts, most likely reflecting differences in the underlying pathophysiology of these distinct genetic disorders."
    explanation: >-
      Records the qualification that matters clinically: the response is real but
      weaker than in DYT1, and the authors attribute that to a genuinely different
      pathophysiology rather than to technique.
discussions:
- discussion_id: dyt6_mouse_does_not_get_dystonia
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    No unprovoked Thap1 mouse develops dystonia, yet a nerve-injured heterozygote
    does. What does the need for a second hit imply about the proposed causal
    chain from transcriptional dysregulation to dystonic movement?
  attaches_to:
  - pathophysiology#Basal Ganglia and Cerebellar Motor Network Dysfunction
  - animal_models#Mouse
  rationale: >-
    This is a mismatch rather than a gap, because the model evidence exists and is
    informative - it simply does not reproduce the phenotype that defines the
    disease. Three things are established in mouse: germline Thap1 deletion is
    embryonic lethal; the heterozygote is rescued by autoregulatory upregulation of
    the intact allele and has no phenotype; and conditional deletion in neural
    precursors produces locomotor deficits and a dystonia-related transcriptional
    signature but not dystonia.

    The mismatch is mechanistically meaningful in two ways. First, the
    autoregulatory rescue is a species difference in gene-dosage handling, which
    means mouse cannot be used to test a haploinsufficiency hypothesis for this
    gene at all. Second, and more consequentially, the step in this entry's
    pathograph from network dysfunction to dystonia is the step no model has
    closed unprovoked: the conditional mouse reaches the network node and stops.
    Human iPSC-derived striatal neurons reach the cellular node and cannot, being
    a dish, address circuit output.

    That framing needs qualifying, and the qualification is the interesting part.
    A peripheral nerve crush in the heterozygote does produce dystonia-like
    movements, exceeding both naive heterozygotes and injured wild-types. So the
    genotype is not phenotypically silent; it is latent. The unanswered question
    shifts from "why does the mouse never get it" to "what does the second hit
    supply". That reframes the human question too, since penetrance in carriers is
    only 40 to 60 per cent, and it is the reason this entry now records the
    gene-environment link on the heterozygous model rather than only the failure.

    What remains genuinely unclosed is whether the injury acts through this
    entry's chain at all. The multi-omic differences reported in nerve-injured
    heterozygotes are energy-metabolism signatures in cerebellum, striatum and
    cortex, which is not obviously the SP1-mediated transcriptional route this
    pathograph models. The final causal edge is therefore still marked inferred.
  proposed_experiments:
  - experiment_id: dyt6_reduced_dosage_without_autoregulation
    name: Knock-in of a patient THAP1 missense allele in a model without Thap1 autoregulation
    description: >-
      Test whether the absent phenotype is due to the autoregulatory rescue rather
      than to a deeper difference in motor circuitry, by using a model organism in
      which the compensating upregulation does not occur, or by engineering an
      allele that escapes autoregulation.
    would_support:
    - pathophysiology#Basal Ganglia and Cerebellar Motor Network Dysfunction
    supporting_outcome:
    - >-
      Dystonic posturing emerges in an animal carrying a reduced-dosage THAP1
      state that is not autoregulatorily rescued, closing the step from network
      dysfunction to dystonia.
    refuting_outcome:
    - >-
      A genuinely reduced-dosage animal still shows locomotor deficit without
      dystonia, which would argue that the human phenotype depends on features of
      primate motor circuitry rather than on THAP1 dosage alone.
  evidence:
  - reference: PMID:30590536
    reference_title: "Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Although these mice do not exhibit dystonia, they show pronounced locomotor deficits reflecting derangements in the cerebellar and basal ganglia circuitry."
    explanation: >-
      The core statement of the mismatch: circuit derangement is reproduced, the
      defining clinical phenotype is not.
  - reference: PMID:30590536
    reference_title: "Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This is because mice show autoregulation of Thap1 mRNA levels with upregulation at the non-affected locus."
    explanation: >-
      Identifies the species difference that makes the heterozygous model
      uninformative, which is the first half of the mismatch.
- discussion_id: dyt6_no_genotype_phenotype_correlation
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Why is there no genotype-phenotype correlation in THAP1 dystonia, and what
    determines penetrance?
  attaches_to:
  - genetic#THAP1
  - pathophysiology#Isolated Dystonia
  rationale: >-
    More than eighty variants are known across several functional classes -
    DNA-binding missense, protein-destabilising missense, HCFC1-binding-motif
    missense, and truncating alleles. Whether they predict phenotype is disputed
    rather than settled: the 2011 review of 56 families found no relationship,
    while a later screen of more than 1800 subjects found that truncating and
    THAP-domain missense variants manifest earlier and involve more body regions.
    Both are cited in the genetic section. Either way the molecular assays curated
    in this entry do not by themselves predict who becomes ill or how severely.

    Penetrance is incomplete at 40 to 60 per cent, so something other than the
    THAP1 allele decides whether a carrier develops dystonia. The environmental
    second hit is no longer purely speculative: a peripheral nerve crush unmasks
    dystonia-like movements in the heterozygous mouse, which is a demonstration in
    principle that a trigger can convert a silent genotype into a phenotype. It is
    not a human exposure, and no precipitant is established in carriers, so the
    practical counselling question stays open.
  evidence:
  - reference: PMID:21793105
    reference_title: "DYT6 dystonia: review of the literature and creation of the UMD Locus-Specific Database (LSDB) for mutations in the THAP1 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Currently, 56 families present with a THAP1 mutation; however, no genotype/phenotype relationship has been found."
    explanation: >-
      States the absence of correlation across the published family set.
  - reference: PMID:32112337
    reference_title: "Unraveling Molecular Mechanisms of THAP1 Missense Mutations in DYT6 Dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Taking together, the current study showed different potential pathogenic mechanisms of THAP1 mutations which lead to the same consequence of DYT6 dystonia."
    explanation: >-
      Supports the convergence of mechanistically distinct variant classes on one
      clinical outcome, which is what makes the absence of correlation coherent
      rather than merely unexplained.

notes: >-
  GeneReviews baseline. The PubMed query `THAP1 AND GeneReviews[All Fields]` (run
  2026-09-13) returns exactly one hit, PMID:20301334 "Monogenic Isolated Dystonia
  Overview". That chapter is on topic for this disorder, unlike the DYT6-specific
  chapter that does not exist. It is cached, and its cached content is only the
  chapter's six-point purpose statement: what the overview intends to describe,
  review and provide. There is no clinical finding, frequency or management
  statement in the cached text, so there is nothing in it that could be quoted as
  an exact-substring snippet. It is therefore recorded here as checked rather than
  mined, and is not cited as evidence anywhere in the entry. If a future pass
  obtains the full chapter text it would be a reasonable phenotype and management
  baseline.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Review round 1: consume the deep-research report the entry was contradicting · 2026-09-13T01:01:13Z · View source

Answers all six blocking findings of the round-1 review in one push. The common cause of five of them was under-consumption of the deep-research report committed in this same PR, and in two places the entry asserted a negative that its own report contradicts. 1. Genotype-phenotype correlation. The entry asserted in three places that none exists, on a 2011 review of 56 families. PMID:22377579 (>1800 subjects) reports the opposite: truncating and THAP-domain missense variants manifest earlier and spread further. Verified in the committed report at finding F011. The description, genetic notes and KNOWLEDGE_GAP rationale now record a genuine dispute rather than a settled negative, and the contradicting sentence is curated as a REFUTE evidence item against the no-correlation claim rather than omitted. 2. Two-hit model. The entry said the mouse does not get the disease. PMID:39732371 shows sciatic nerve crush in Thap1+/- mice produces significantly more dystonia-like movements than in naive heterozygotes and than in injured wild-types. Added as a second modeled_mechanisms link on the same animal model, PARTIALLY_RECAPITULATES against Isolated Dystonia at ORGANISM scale, with a SPECIES_MISMATCH divergence marked QUALIFYING because a nerve crush is not a human precipitant. The existing FAILS_TO_RECAPITULATE link against the molecular node is kept and is still correct: it concerns steady-state dosage, which autoregulation does rescue. The HUMAN_MODEL_MISMATCH prompt and rationale were rewritten, since their premise was false. 3. DBS evidence. The treatment notes claimed no publication reported outcomes in genotyped THAP1 patients. False, and falsifiable from this PR's own report. PMID:31817799 is a genotyped multicentre cohort with a median 58 percent reduction; PMID:21949105 records that the response is weaker than in DYT1. Both curated; the false claim is replaced by a note saying what it was. 4. Botulinum toxin modality. SMALL_MOLECULE was wrong for a roughly 150 kDa bacterial protein. Changed to OTHER, with the reasoning recorded. PEPTIDE would be nearly as wrong at that size and PROTEIN_REPLACEMENT does not apply. A KB-wide scan found botulinum treatments carrying SMALL_MOLECULE about as often as OTHER, which is worth a separate sweep. 5. GeneReviews. Recorded in a new top-level notes block per the Neurodevelopmental_Disorder_with_Hypotonia_and_Speech_Delay convention: the query THAP1 AND GeneReviews[All Fields] run 2026-09-13 returns exactly one hit, PMID:20301334, whose cached content is only the chapter's six-point purpose statement with no quotable clinical finding. Checked rather than mined, and not cited. 6. TOR1A derepression. Added as a distinct MOLECULAR pathophysiology node with a downstream edge from Reduced THAP1 Transcriptional Regulatory Function, citing PMID:20976771 and PMID:20865765. This is THAP1's best-characterised direct target and the molecular bridge to DYT1. No downstream edge is asserted from it, because how much of the dystonia is attributable to TOR1A derepression rather than the wider SP1-mediated change is not established. Non-blocking items also taken: penetrance quantified at 40-60 percent and mean onset age 16.8 years, both now cited; an oral pharmacotherapy tier added from PMID:31117876. Process failure worth recording: three reference_title values in this round were written from inference rather than read from the cache, and all three were wrong. Reference validation caught all three. They were replaced by reading the title: frontmatter programmatically. This is the same failure class the titles convention exists to prevent, committed while fixing a review about evidence discipline. Validation: 51/51 snippets verified, schema and terms pass.

Create: Torsion Dystonia 6 (THAP1, MONDO:0011264) · 2026-09-12T13:22:06Z · View source

De novo curation of torsion dystonia 6 (DYT6, DYT-THAP1) from claim issue #11739. Curated as a Disease distinct from the existing Cervical_Dystonia entry. That entry covers common adult-onset sporadic focal cervical dystonia, deliberately binds no causal gene, and types THAP1 as SUSCEPTIBILITY on the grounds that these genes explain a small minority of unselected cases; the cohort cited here puts THAP1 at 1.8 percent of an unselected primary dystonia series. DYT6 is the Mendelian entity itself: one gene, dominant transmission with reduced penetrance, characteristic early-onset craniocervical and laryngeal involvement with limb spread. The pathograph runs from heterozygous THAP1 loss-of-function variants through reduced THAP1 transcriptional regulatory function, transcriptional dysregulation executed through the SP1 family, and reduced striatal GABAergic transmission, to basal ganglia and cerebellar motor network dysfunction and isolated dystonia. Three distinct molecular routes to the second node are curated separately because they are separately demonstrated: impaired DNA binding, reduced protein stability, and abolished HCFC1 cofactor recruitment at promoters where DNA binding is intact. The entry is built to show where the chain is strong and where it is not. The molecular and cellular ends are supported by human in vitro work including patient-derived iPSC striatal medium spiny neurons. The final edge from network dysfunction to dystonia is inferred and is marked as such: no curated study demonstrates it in humans, and no model reaches it. Model mismatch is recorded structurally rather than as prose. Germline Thap1 deletion is embryonic lethal; the heterozygote, the genotype that should model human haploinsufficiency, is rescued by autoregulatory upregulation of the intact allele and has no phenotype; conditional nervous-system deletion gives locomotor deficits and a dystonia-related transcriptional signature but not dystonia. These are two AnimalModel records with FAILS_TO_RECAPITULATE and PARTIALLY_RECAPITULATES links, typed divergences, and a HUMAN_MODEL_MISMATCH discussion carrying a proposed experiment. Deep research: one openscientist report was run and is committed alongside the entry. just preflight-dr returned PASS. The report's own Term Validation section flagged four genuine ontology confabulations, and none reached this entry because every CURIE here was read from cache/ or an OAK lookup at the moment it was written: HP:0002408 offered as Torticollis is Cerebral arteriovenous malformation (entry uses HP:0000473), HP:0001350 offered as Dysphonia is Slurred speech (entry uses HP:0012049 Laryngeal dystonia), NCIT:C1084 offered as botulinum toxin is Staphylococcal Enterotoxin B (entry uses no agent term and says why), and NCIT:C38150 offered as deep brain stimulation is PEComa (entry uses NCIT:C21024). A fifth identifier, HP:0004350, does not exist in HPO. The report did not repeat the THAP1/THAP11 confusion of issue #10948; it uses HGNC:20856 correctly. Schema notes for reviewers. One divergence is typed OTHER because ModelDivergenceTypeEnum has no value for a model that reproduces the mechanism but not the phenotype. CLAUDE.md names INCOMPLETE_PHENOTYPE as a likely future addition to that enum and I initially used it; schema validation rejected it, correctly, and the description records the substitution. Several phenotype evidence items carry directness: INDIRECT with an explanation stating that the cached abstract establishes cranial or craniocervical involvement without naming the individual body region. That is recorded rather than smoothed over, because the alternative was to attach a quote that does not say what the phenotype claims. Validation: just validate passed with 40/40 snippets verified; just validate-terms passed; check-duplicate-keys, check-entity-refs, check-causal-targets and check-qualifier-terms all clean.

OpenScientist ▸
Torsion Dystonia 6 (DYT6 / DYT-THAP1): Comprehensive Disease Characteristics Report
openscientist-autonomous 37 citations 2026-09-12T13:12:28.131385

Torsion Dystonia 6 (DYT6 / DYT-THAP1): Comprehensive Disease Characteristics Report

MONDO: MONDO:0011264 · OMIM: #602629 (DYSTONIA 6, TORSION; DYT6) · Gene: THAP1 (OMIM *609520; HGNC:20856; 8p11.21) · Category: Mendelian, autosomal dominant

Evidence base: This report is synthesized from primary human clinical/genetic studies, in-vitro molecular biology, structural biology, and animal models identified via PubMed (49 papers reviewed, 12 confirmed findings). Source types are flagged inline. Where a specific figure is not firmly established in the retrieved literature, this is stated explicitly. No patient-level data files were provided; this is a literature-derived, disease-level report.

Summary

Torsion Dystonia 6 (DYT6, now designated DYT-THAP1) is a rare, autosomal dominant, incompletely penetrant form of isolated (primary) torsion dystonia caused by heterozygous loss-of-function mutations in THAP1, which encodes a THAP-domain zinc-finger transcription factor. It was the first transcription factor implicated in primary dystonia, established by Fuchs et al. (2009), who identified THAP1 mutations in three Amish–Mennonite families with mixed-onset primary torsion dystonia (PMID: 19182804). DYT6 is clinically distinguished from DYT1 (TOR1A) dystonia by its predilection for the craniocervical region, larynx (producing spasmodic/laryngeal dysphonia), and upper limbs, with frequent progression to segmental or generalized dystonia. Mean age at onset is approximately 16.8 years (range 3 to >60), and penetrance is estimated at only 40–60%.

Mechanistically, DYT6 sits at the center of a shared dystonia gene-regulatory network. Wild-type THAP1 binds and represses the core promoter of TOR1A (the DYT1 gene) and autoregulates its own promoter; pathogenic mutations abolish DNA binding and de-repress these targets, linking DYT6 and DYT1 in a common transcriptional pathway. Downstream, THAP1 dysregulates gene programs largely through the SP1/SP4 transcription-factor family in a cell-type–dependent manner, affecting synaptic transmission, cytoskeletal genes, and dopaminergic (specifically D2-receptor / indirect-pathway) signaling in the basal ganglia, with additional convergent abnormalities in the deep cerebellar nuclei. There is no neurodegeneration; the disorder is a network-level functional dysregulation across the basal ganglia–thalamo-cortical and cerebellar circuits.

Diagnosis is molecular (THAP1 sequencing or whole-exome sequencing), and treatment is entirely symptomatic and stepwise: oral agents (anticholinergics, baclofen, benzodiazepines), botulinum toxin chemodenervation for focal features including laryngeal dystonia, and globus pallidus internus (GPi) deep brain stimulation for refractory generalized disease — the last being effective but generally less robust than in DYT1. No disease-modifying therapy exists.

Key Findings

F001 — DYT6 is caused by autosomal dominant loss-of-function mutations in the transcription factor THAP1

DYT6 dystonia was defined molecularly when Fuchs and colleagues discovered mutations in THAP1 in three Amish–Mennonite families with mixed-onset primary torsion dystonia. As stated in the primary paper: "We report the discovery of a mutation in the THAP1 gene in three Amish-Mennonite families with mixed-onset primary torsion dystonia (also known as DYT6 dystonia)" and "We demonstrate that the missense mutation impairs DNA binding, suggesting that transcriptional dysregulation may contribute to the phenotype of DYT6 dystonia" (PMID: 19182804). THAP1 is the first transcription factor implicated in primary dystonia. The inheritance pattern and mechanism were confirmed by later work: "Dystonia 6 (DYT6) is an autosomal dominant dystonia caused by loss-of-function mutations in the zinc finger transcription factor THAP1" (PMID: 30590536). A locus-specific database (UMD-THAP1 LSDB) subsequently cataloged 56 probands and 43 relatives, finding no clear genotype–phenotype correlation at that time (PMID: 21793105). (Evidence: human genetic; in-vitro.)

F002 — THAP1 represses TOR1A (DYT1) and autoregulates its own promoter, linking the two primary dystonia genes

Two independent groups demonstrated a direct molecular link between DYT6 and DYT1. Kaiser et al. showed by EMSA/ChIP that "THAP1 binds to the core promoter of TOR1A. Further, we report that wild type THAP1 represses the expression of TOR1A, whereas dystonia 6-associated mutant THAP1 results in decreased repression of TOR1A" (PMID: 20976771). Gavarini et al. independently confirmed "a physical interaction between THAP1 and the TOR1A promoter that is abolished by pathophysiologic mutations" (PMID: 20865765). THAP1 also regulates itself: Erogullari et al. "identified a feedback-loop in the regulation of THAP1 expression and demonstrated that mutant THAP1 leads to higher THAP1 expression levels. This compensatory autoregulation may contribute to the mean age at onset" (PMID: 25088175). This positions THAP1 as an upstream master regulator whose loss de-represses TOR1A and perturbs its own dosage. (Evidence: in-vitro molecular biology.)

F003 — Pallidal (GPi) deep brain stimulation improves DYT6 but less robustly than DYT1

In a multicenter cohort (n=14, median 4.8-year follow-up), "All benefited from surgery: dystonia severity was reduced by a median of 58%" (BFMDRS motor, IQR 31–62) (PMID: 31817799). However, comparative work found "DYT6 patients appear to respond less robustly to GPi-DBS than their DYT1 counterparts, most likely reflecting differences in the underlying pathophysiology of these distinct genetic disorders" (PMID: 21949105), with some regression observed in years 2–3 despite comparable GPi microelectrode firing patterns between the two genotypes. (Evidence: human clinical.)

F004 — Characteristic phenotype: early-onset craniocervical, laryngeal, and brachial dystonia that often generalizes

Unlike DYT1, "the symptoms of DYT6 dystonia frequently involve the craniocervical region" (PMID: 19345148). Laryngeal involvement is a signature feature: in three DYT6 families, "In all three symptomatic MutC, early-onset laryngeal dystonia was a prominent feature. Laryngeal assessment demonstrated adductor-type dystonia in all of them", and transcranial sonography "revealed increased substantia nigra (SN) hyperechogenicity in all MutC" (PMID: 20687193). Spasmodic dysphonia (voice-affecting laryngeal dystonia) is therefore a hallmark early manifestation. (Evidence: human clinical.)

F005 — THAP1 protein architecture: N-terminal DNA-binding zinc finger + C-terminal coiled-coil dimerization domain; most mutations are missense in the DNA-binding domain

The N-terminal atypical C2CH THAP zinc finger recognizes DNA via an unusual mechanism: "The THAP zinc finger uses its double-stranded beta-sheet to fill the DNA major groove" (PMID: 20144952). Variant distribution and consequences are well defined: "most pathogenic THAP1 mutations are missense and are located in the DNA-binding domain. There are also nonsense mutations, which act as the equivalent of a null allele because they result in the generation of small mRNA species that are likely rapidly degraded via nonsense-mediated decay" (PMID: 26376866). The C-terminus contains "a coiled-coil domain (amino acids 139-190) towards its C-terminus postulated as a protein-protein-binding motif" that mediates homodimerization (PMID: 28299530). (Evidence: structural biology; in-vitro.)

F006 — THAP1 accounts for ~1–2% of primary/isolated dystonia, enriched in early-onset, familial, non-focal cases

In a large Spanish cohort (n=1053), "Pathogenic or likely pathogenic variants in TOR1A, THAP1 and GNAL were identified in 0.48%, 0.57% and 0.29% of our patients, respectively", and across the literature "variations in TOR1A, THAP1 or GNAL accounted for about 6%, 1.8% and 1.1% of published dystonia patients, respectively" (PMID: 33175450). In a Chinese WES cohort of 88 isolated-dystonia patients, TOR1A + THAP1 together accounted for 47% of molecularly diagnosed cases (PMID: 36648081). Italian screening "strengthen[ed] the association with upper body involvement, including the cranial and cervical districts that are usually spared in DYT1-PTD" (PMID: 19908325), and THAP1 mutations have been confirmed across ancestries (India, PMID: 27913194). (Evidence: human genetic epidemiology.)

F007 — Thap1 animal models: no overt dystonia, but motor deficits, cerebellar and dopaminergic abnormalities, and convergent transcriptional changes

Mouse and rat models recapitulate molecular and motor but not overtly dystonic phenotypes. In the C54Y knock-in and null models, "The projection neurons of the deep cerebellar nuclei are especially altered" (PMID: 26376866); homozygous germline null is embryonic lethal. Nervous-system Thap1 deletion causes locomotor deficits with transcriptional changes in synaptic transmission, cytoskeleton, gliosis, and dopamine signaling (PMID: 30590536). Pharmacological probing revealed "depleting THAP1 specifically interferes with the D2 receptor responses, pointing to a selective misregulation of the indirect pathway in DYT6" (PMID: 34802187). The downstream effector network is largely SP1/SP4-mediated: "THAP1 mutations lead to dysregulation of genes mainly through regulation of SP1 family members, SP1 and SP4, in a cell type dependent manner" (PMID: 35015830). (Evidence: model organism.)

F008 — THAP1's canonical molecular function: pRB/E2F cell-cycle regulator partnering with HCF-1 and O-GlcNAc transferase, linking DYT6 to DYT3

THAP1 was first characterized as a cell-cycle regulator: "THAP1-mediated growth inhibition is due to coordinated repression of pRB/E2F cell-cycle target genes" including RRM1 (PMID: 17003378). It associates with the transcriptional coactivator HCF-1 and O-GlcNAc transferase (OGT), establishing "a link between DYT6 and DYT3 dystonias" — the X-linked dystonia-parkinsonism pathway (PMID: 20200153). This positions THAP1 within a broader transcriptional-regulatory hub connecting multiple monogenic dystonias. (Evidence: in-vitro molecular biology.)

F009 — Treatment is symptomatic and stepwise

Dystonia management follows a tiered algorithm. "Oral anticholinergics, baclofen and clonazepam are used off-label" and "Chemodenervation with botulinum toxin remains the treatment of choice for focal- or select-body regions in generalized and segmental dystonia" (PMID: 31117876). A recent review summarizes: "Treatment follows a stepwise strategy, beginning with oral pharmacologic agents like anticholinergics and levodopa (especially in dopamine-related dystonias), progressing to botulinum toxin injections and deep brain stimulation of the globus pallidus internus in refractory cases" (PMID: 40841848). No disease-modifying therapy exists. (Evidence: clinical guidelines/review.)

F010 — THAP1 is a rare cause of isolated laryngeal dystonia within a distributed network disorder with genotype-specific structural signatures

Screening of 86 spasmodic dysphonia patients found "Two patients tested positive for novel/rare variants in THAP1 (DYT6)" (PMID: 27188707). Imaging demonstrates that laryngeal dystonia is a network disorder with genotype-dependent structural correlates: "Genotype-specific alterations were found in the left superior temporal gyrus, supplementary motor area, and the arcuate portion of the left superior longitudinal fasciculus" (PMID: 28186656). The broader isolated-dystonia network involves cerebellar/cholinergic dysfunction; e.g., in DYT1, "In the cerebellar vermis, VAChT expression was also significantly decreased in patients versus controls" (PMID: 33638639). (Evidence: human clinical/imaging.)

F011 — Quantitative natural history: mean onset ~16.8 years, neck most affected, genotype–phenotype correlation, penetrance 40–60%

A large screening study (>1800 subjects) established that "mean age of onset for THAP1 dystonia is 16.8 years and the most common sites of onset are the arm and neck, and the most frequently affected anatomical site is the neck", with more than half of patients having cranial or laryngeal involvement. Critically, a genotype–phenotype correlation exists: "Protein truncating mutations and missense mutations within the THAP domain of THAP1 tend to manifest at an earlier age and exhibit more extensive anatomical distributions" (PMID: 22377579). Penetrance is incomplete — "The incomplete penetrance of DYT-THAP1 dystonia, estimated at 40 to 60 %" (PMID: 39732371). (Evidence: human clinical/genetic.)

F012 — Gene–environment "two-hit" model and metabolic dysregulation; cerebellar and late-onset presentations exist

A multi-omics study demonstrated an environmental trigger unmasking genetic predisposition: "we performed a sciatic nerve crush injury in a genetically predisposed DYT-THAP1 heterozygous knockout mouse model", which induced dystonia-like movements and energy-metabolism dysregulation (PMID: 39732371). In-vivo human cerebellar involvement was shown in a 51-year-old carrier with ataxia: "The lack of CBI [cerebellar brain inhibition] in our patient strongly suggests cerebellar involvement" (PMID: 31367947). Late-onset disease (onset ≥40y) is predominantly cranial and sporadic: "Cranial dystonia was the most common site of onset (n = 22), followed by cervical (n = 13), while limb onset was uncommon" (PMID: 42371050). (Evidence: model organism; human clinical.)

Section-by-Section Report

1. Disease Information

Overview. Torsion Dystonia 6 (DYT6, DYT-THAP1) is a rare Mendelian, autosomal dominant form of isolated torsion dystonia — sustained or intermittent muscle contractions causing abnormal, often repetitive movements and postures — without neurodegeneration or additional neurological features in its pure form. It characteristically begins in childhood or adolescence in the craniocervical, laryngeal, or upper-limb regions and frequently spreads to become segmental or generalized (F001, F004, F011).

Key identifiers. MONDO:0011264 · OMIM #602629 (phenotype) / THAP1 *609520 · Gene: THAP1 (HGNC:20856), 8p11.21. Orphanet: DYT-THAP1 (within isolated dystonia grouping). MeSH: Dystonic Disorders / Dystonia (no unique DYT6 heading). ICD-11: 8A02.1 (dystonia). ICD-10: G24.1 (idiopathic familial dystonia) / G24.8.

Synonyms. DYT6; DYT-THAP1; dystonia 6, torsion (autosomal dominant); THAP1-related dystonia; primary torsion dystonia type 6; mixed-onset primary torsion dystonia (historical, Amish–Mennonite).

Data source. Aggregated disease-level resources (OMIM, Orphanet, UMD-THAP1 LSDB [PMID: 21793105]) and published clinical case series/cohorts — not EHR/individual-patient registries.

2. Etiology

Causal factors. Primary cause is genetic: heterozygous loss-of-function mutations in THAP1 (F001). Most are missense in the DNA-binding THAP domain; nonsense/frameshift variants act as null alleles via nonsense-mediated decay (F005). Mechanism is transcriptional dysregulation (loss of DNA binding → de-repression of downstream targets).

Genetic risk factors. The causal THAP1 variant is dominant. Genotype modifies severity: protein-truncating and THAP-domain missense mutations produce earlier onset and more extensive distribution (F011). A founder missense mutation was originally described in Amish–Mennonite families (F001, F006).

Environmental risk factors. No established human environmental risk factors. A gene–environment "two-hit" model is supported experimentally: peripheral nerve (sciatic crush) injury unmasks dystonia-like movements in Thap1+/- mice (F012) — plausible but unproven in humans.

Protective factors. None established. Incomplete penetrance (40–60%) implies unidentified genetic modifiers and/or environmental buffers protect a large fraction of carriers (F011).

Gene–environment interaction. The two-hit model (genetic predisposition + peripheral injury/metabolic stress) is the leading GxE framework (F012).

3. Phenotypes

Phenotype Type HPO suggestion Onset Severity/Course Frequency
Torsion/isolated dystonia Clinical sign HP:0001332 (Dystonia) Childhood–adolescence (mean 16.8 y) Progressive → generalized Defining, ~100%
Cervical dystonia Clinical sign HP:0002408 (Torticollis) Early Progressive Neck = most affected site
Laryngeal dystonia / spasmodic dysphonia Clinical sign HP:0001350 (Dysphonia) Early, prominent Chronic >50% cranial/laryngeal
Craniofacial (blepharospasm, oromandibular) Clinical sign HP:0000643; HP:0002019 Childhood–adult Segmental Common
Dysarthria/speech difficulty Symptom HP:0001260 Early Chronic Common
Limb (arm) dystonia Clinical sign HP:0004350 Common onset site Progressive Common onset
Generalized dystonia Clinical sign HP:0007325 Follows focal onset Progressive Frequent

Characteristics. Mean onset ~16.8 years (range 3 to >60); most common onset sites arm and neck; neck most frequently affected; >50% have cranial/laryngeal involvement; typically progressive from focal to segmental/generalized (F004, F011). Late-onset (≥40y) presentations are predominantly cranial and sporadic (F012). Severity is variable, consistent with incomplete penetrance and variable expressivity.

Quality of life. Laryngeal dystonia selectively impairs speech/communication; generalized dystonia impairs mobility and daily function. No DYT6-specific EQ-5D/SF-36 data available; general dystonia burden is substantial.

4. Genetic / Molecular Information

Causal gene. THAP1 (HGNC:20856; OMIM 609520; 8p11.21), encoding a 213-aa zinc-finger transcription factor (F001, F005).

Protein architecture. N-terminal atypical C2CH THAP zinc-finger DNA-binding domain (double-stranded β-sheet inserted into the major groove; bipartite major+minor groove recognition, consensus ~TXXGGGX(A/T)); nuclear localization signal; C-terminal coiled-coil homodimerization domain (aa ~139–190) (F005; PMID: 20010837).

Pathogenic variants. Predominantly missense in the DNA-binding domain (e.g., Ser6Phe, Arg13His [also destabilizing], C54Y/C54F, L180S); also nonsense/frameshift acting as null alleles via NMD (F005). ClinVar/HGMD list dozens of P/LP variants; population allele frequencies are very low (rare disease); most are private/family-specific. Origin: germline; autosomal dominant. Functional consequence: loss of function (F001, F002, F005). Truncated mutants can mislocalize partly to cytoplasm; some missense mutants remain nuclear (PMID: 22652465).

Modifier genes. Not definitively identified; incomplete penetrance implies modifiers exist. THAP1 autoregulates (F002); downstream, SP1/SP4 mediate effects (F007).

Epigenetic information. THAP1 partners with HCF-1 and O-GlcNAc transferase (OGT), tying it to chromatin/coactivator complexes and linking DYT6 to DYT3 (F008). No disease-specific methylation signature established.

Chromosomal abnormalities. None characteristic; DYT6 is a single-gene point-mutation disorder.

5. Environmental Information

No established environmental toxin, radiation, lifestyle, or infectious etiology. The only experimental environmental contributor is peripheral nerve injury acting as a "second hit" in genetically predisposed Thap1+/- mice, with accompanying energy-metabolism dysregulation (F012). Infectious agents are not implicated (distinct from secondary dystonias such as post–Japanese encephalitis dystonia, PMID: 35025122).

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

  1. A heterozygous loss-of-function mutation in THAP1 (missense in the DNA-binding domain, or an NMD-degraded null allele) leads to reduced functional THAP1 transcription-factor activity. (demonstrated)
  2. Reduced THAP1 DNA-binding results in de-repression of its direct target TOR1A (the DYT1 gene) and dysregulated THAP1 autoregulation (altered THAP1 dosage). (demonstrated in vitro)
  3. In parallel, loss of THAP1 leads to broad transcriptional dysregulation executed largely through the SP1/SP4 transcription-factor family in a cell-type–dependent manner. (demonstrated in models)
  4. These transcriptional changes result in altered expression of genes governing synaptic transmission, cytoskeleton, and dopaminergic signaling — with selective impairment of D2-receptor/indirect-pathway responses in striatum, plus abnormalities of deep cerebellar nuclei projection neurons. (demonstrated in mouse models)
  5. Branch A (basal ganglia): indirect-pathway/D2 dysfunction leads to imbalanced basal ganglia–thalamo-cortical output. Branch B (cerebellum): deep cerebellar nuclei/vermis dysfunction leads to abnormal cerebellar contribution to the motor network. (inferred: model + human imaging integration)
  6. Convergent basal ganglia + cerebellar network dysfunction results in aberrant sensorimotor integration and loss of surround inhibition. (inferred)
  7. This manifests as isolated dystonia — craniocervical, laryngeal, and brachial, frequently generalizing — typically in adolescence, in ~40–60% of carriers. (demonstrated clinically)
  8. Optional environmental branch: a peripheral "second hit" (nerve injury/metabolic stress) can unmask or trigger dystonia in predisposed carriers. (demonstrated in mice; inferred in humans)

Molecular pathways. THAP1 → TOR1A repression (F002); THAP1 → SP1/SP4-dependent network (F007); THAP1 → pRB/E2F cell-cycle targets incl. RRM1 (canonical, F008); THAP1–HCF-1–OGT complex linking to DYT3 (F008). Suggested GO biological processes: GO:0006355 (regulation of transcription), GO:0000122 (negative regulation of transcription by RNA pol II), GO:0007399 (nervous system development), GO:0007268 (chemical synaptic transmission), dopamine receptor signaling (D2/indirect pathway).

Cellular processes. Neuronal transcriptional regulation; synaptic transmission; dopaminergic indirect-pathway signaling; cytoskeletal regulation; gliosis (F007). No apoptosis/neurodegeneration in the primary disease.

Cell types & anatomy. Striatal D2 medium spiny neurons (indirect pathway; CL:0002613), deep cerebellar nuclei projection neurons, cortical sensorimotor neurons; neuron–glia interactions implicated (PMID: 38737544). Suggested CL terms: CL:0000540 (neuron), CL:0002613 (striatal neuron), CL:0000127 (astrocyte).

Molecular profiling. Transcriptomic studies in Thap1 models show convergent dysregulation of synaptic, cytoskeletal, dopaminergic, and gliosis genes (F007). DTI in patients shows reduced fractional anisotropy in sensorimotor white matter ([PMID: 22652465]). Metabolic/energy-pathway dysregulation in the two-hit mouse (F012).

7. Anatomical Structures Affected

  • Organ/system: Central nervous system — motor control circuitry (UBERON:0001017 CNS; UBERON:0000955 brain). Body system: nervous system.
  • Primary regions: Basal ganglia (UBERON:0002420), especially striatum/putamen (UBERON:0001874) and globus pallidus internus (DBS target, UBERON:0002477); substantia nigra (SN hyperechogenicity, F004); cerebellum (UBERON:0002037), especially deep cerebellar nuclei and vermis (F007, F010, F012).
  • Cortical/network: Sensorimotor cortex, supplementary motor area, superior temporal gyrus, superior longitudinal fasciculus (genotype-specific structural changes, F010); thalamo-cortical loops.
  • Tissue/cell: Nervous tissue; striatal D2 medium spiny neurons, deep cerebellar nuclei projection neurons (F007).
  • Subcellular: Nucleus (transcription factor; GO:0005634); mutant truncations partly cytoplasmic (GO:0005737) ([PMID: 22652465]).
  • Lateralization: May begin focally/asymmetrically but frequently becomes bilateral/segmental/generalized (F004, F011).

8. Temporal Development

  • Onset: Childhood to adolescence, mean ~16.8 years (range 3 to >60); insidious/chronic onset (F011). Late-onset (≥40y) subset predominantly cranial and sporadic (F012).
  • Progression: Typically progressive spread from focal onset (arm/neck) to segmental or generalized dystonia; neck most affected (F004, F011). Chronic, lifelong; not self-limited. Genotype influences rate/extent — truncating and THAP-domain missense mutations → earlier, more extensive disease (F011).
  • Patterns: No characteristic spontaneous remission; symptomatic improvement is treatment-induced (botulinum toxin, DBS). Adolescence is the critical vulnerability window; DBS can benefit refractory cases (F003).

9. Inheritance and Population

  • Inheritance: Autosomal dominant (F001).
  • Penetrance: Incomplete, ~40–60% (F011).
  • Expressivity: Variable — onset, distribution, and severity vary, partly by mutation type/location (F011).
  • Epidemiology: THAP1 pathogenic variants in ~0.57% of a large dystonia cohort and ~1.8% of published dystonia patients (F006). Absolute prevalence/incidence not precisely established (rare disease). Founder mutation in Amish–Mennonite populations; confirmed across European, Chinese, Indian ancestries (F006).
  • Anticipation/mosaicism/consanguinity: No repeat-expansion anticipation (point-mutation disorder). Germline mosaicism not specifically characterized. Consanguinity not required (dominant).
  • Sex ratio/age distribution: No strong sex predilection established; onset concentrated in childhood–adolescence with a late-onset tail.

10. Diagnostics

  • Genetic testing (definitive): Sequencing of THAP1 (single-gene or dystonia gene panel) or WES/WGS; WES is high-yield in early-onset/familial isolated dystonia (F006). Recommended: dystonia panel or WES including TOR1A, THAP1, GNAL, TUBB4A, PRKRA, ANO3.
  • Imaging: Brain MRI typically normal. Research findings: transcranial sonography SN hyperechogenicity (F004); DTI reduced sensorimotor white-matter FA ([PMID: 22652465]); network/QSM imaging shows distributed sensorimotor–basal ganglia–cerebellar abnormalities (F010).
  • Electrophysiology: TMS shows reduced cerebellar brain inhibition (CBI) in some carriers (F012); laryngeal EMG documents adductor-type laryngeal dystonia (F004).
  • Laboratory/biomarkers: No specific fluid biomarker; diagnosis is genetic and clinical.
  • Clinical criteria & differential diagnosis: Isolated dystonia phenotype (MDS consensus classification). Differentials: DYT1 (TOR1A — limb onset, spares cranial region), DYT25 (GNAL, PMID: 27093447), DYT4 (TUBB4A), DYT-PRKRA (PMID: 40879515), dopa-responsive dystonia, Wilson disease, tardive/secondary dystonias.
  • Screening: No population newborn screening; cascade genetic testing and counseling for at-risk relatives is appropriate given AD inheritance with incomplete penetrance.

11. Outcome / Prognosis

  • Survival/mortality: Normal life expectancy; non-degenerative and not directly life-shortening.
  • Morbidity/function: Chronic motor disability from generalized/segmental dystonia; laryngeal involvement impairs speech/communication. Substantial QoL impact.
  • Disease course: Progressive spread is common but plateaus; chronic and lifelong (F011).
  • Recovery/treatment response: Symptomatic improvement achievable — GPi-DBS reduces severity by a median ~58%, less robustly than DYT1 with possible partial regression (F003).
  • Prognostic factors: Mutation type/location (truncating/THAP-domain missense → earlier, more extensive disease) (F011); genotype (DYT6 vs DYT1) predicts DBS response (F003).

12. Treatment

Stepwise, symptomatic, no disease-modifying therapy (F009):

Tier Intervention Notes NCIT suggestion
1 Oral anticholinergics (trihexyphenidyl), baclofen, benzodiazepines (clonazepam) Off-label; modest benefit in generalized dystonia NCIT:C285 (anticholinergic agent); NCIT:C61703 (baclofen)
2 Botulinum toxin chemodenervation (EMG-guided for laryngeal/focal) Treatment of choice for focal/select regions incl. spasmodic dysphonia NCIT:C1084 (botulinum toxin)
3 GPi deep brain stimulation For refractory generalized/segmental disease; ~58% median improvement, less robust than DYT1 NCIT:C38150 (deep brain stimulation)
  • Pharmacogenomics: Not established for DYT6.
  • Advanced/experimental: No approved gene/RNA therapy; dosage-restoring or transcription-network-normalizing approaches are a future prospect. Levodopa is generally ineffective in DYT6 (reserved for dopa-responsive dystonias).
  • Surgical outcomes: GPi-DBS benefits all treated patients in cohorts, with genotype-dependent variability (F003). Pediatric DBS carries higher major-complication rates in movement disorders vs other indications (PMID: 41071966).
  • Rehabilitation/supportive: Physical, occupational, and speech therapy for functional support.

13. Prevention

  • Primary prevention: Not applicable beyond reproductive options. Genetic counseling for at-risk families; preimplantation/prenatal testing possible where a familial pathogenic variant is known.
  • Secondary prevention: Cascade genetic testing of relatives; early diagnosis enables timely symptomatic intervention.
  • Tertiary prevention: Optimizing botulinum toxin/DBS to prevent contractures and functional decline.
  • Counseling: Autosomal dominant with 40–60% penetrance and variable expressivity — key counseling points (F011). No immunization/public-health interventions applicable.

14. Other Species / Natural Disease

  • Taxonomy/orthologs: THAP1 orthologs exist in mouse (Thap1, NCBI Gene 100210), rat, and other mammals; THAP-domain proteins are conserved across eukaryotes (F005, F008).
  • Natural disease: No well-documented naturally occurring DYT6-equivalent dystonia in companion animals or wildlife (no established OMIA entry for this specific disorder).
  • Comparative biology: Mechanisms are studied via engineered rodent models, not natural animal disease. THAP-domain transcriptional regulation is evolutionarily conserved.
  • Transmission: Not applicable (non-infectious, non-zoonotic).

15. Model Organisms

  • Mammalian models: Mouse Thap1 C54Y knock-in and null alleles; homozygous germline null is embryonic lethal (F007). Nervous-system-specific conditional deletions cause locomotor deficits with transcriptional dysregulation (F007). Rat models also described.
  • Phenotype recapitulation: Models reproduce molecular (transcriptional dysregulation, D2/indirect-pathway deficits, deep cerebellar nuclei abnormalities) and motor phenotypes, but do not show overt dystonia — a key limitation (F007). Heterozygotes show mRNA autoregulation and typically no overt phenotype unless challenged by a second hit (nerve injury; F012).
  • Applications: Dissecting THAP1's transcriptional targets (SP1/SP4), dopaminergic circuitry, cerebellar contribution, and gene–environment interactions (F007, F012).
  • Resources: MGI (mouse Thap1); cellular systems (HEK-293T transfection of mutant clones, [PMID: 22652465]); iPSC/organoid models are emerging.

Mechanistic Model / Interpretation

   THAP1 LoF mutation (missense in DNA-binding domain, or NMD-degraded null)
    │  (loss of DNA binding)
    ▼
Reduced THAP1 transcriptional repression
  │                         │
  ▼                         ▼
   De-repression of TOR1A     SP1/SP4-dependent gene-network
   (links DYT6 ↔ DYT1)        dysregulation (cell-type specific)
  │                         │
  └───────────┬─────────────┘
      ▼
   Altered synaptic / cytoskeletal / dopaminergic gene expression
      │
┌─────────────┴──────────────┐
▼                            ▼
  Basal ganglia branch:        Cerebellar branch:
  D2 / indirect-pathway         deep cerebellar nuclei
  dysfunction (striatum)        + vermis abnormalities
└─────────────┬──────────────┘
      ▼
   Network-level sensorimotor dysintegration; loss of surround inhibition
      │        ▲
      │        └── optional "second hit": peripheral nerve
      ▼            injury / metabolic stress (unmasks disease)
   Isolated dystonia: craniocervical, laryngeal, brachial → generalizes
   (mean onset ~16.8 y; penetrance 40–60%; no neurodegeneration)

DYT6 is fundamentally a transcriptional-network disorder rather than a neurodegenerative one. THAP1 acts as an upstream hub whose loss propagates through two demonstrated arms — direct de-repression of TOR1A (unifying DYT6 with DYT1) and SP1/SP4-mediated dysregulation of neuronal gene programs — converging on dopaminergic (D2/indirect-pathway) and cerebellar circuit dysfunction. The clinical corollary is a distributed basal ganglia–thalamo-cortical + cerebellar network abnormality with genotype- and phenotype-specific structural signatures, explaining both the craniocervical/laryngeal predilection and the partial, less-robust response to GPi-DBS compared with DYT1. Incomplete penetrance plus the experimental two-hit model implies that manifestation depends on additional genetic modifiers and/or environmental triggers.

Evidence Base

PMID Title (abbrev.) Supports
19182804 THAP1 mutations cause DYT6 F001 — gene discovery, LoF
30590536 Loss of Thap1 → convergent transcriptional deficits F001, F007
20976771 DYT1 repressed by THAP1 F002 — TOR1A repression
20865765 Direct DYT1–DYT6 interaction F002
25088175 THAP1 autoregulation F002
31817799 GPi-DBS in DYT6 F003 — 58% improvement
21949105 Pallidal DBS DYT6 vs DYT1 F003 — less robust
19345148 DYT6 + spasmodic dysphonia F004 — craniocervical
20687193 DYT6 imaging/electrophysiology F004 — laryngeal, SN echo
20144952 THAP zinc finger structure F005 — DNA binding
26376866 Thap1 mouse motor/cerebellar F005, F007
28299530 THAP1 dimerization domain F005
33175450 GNAL/THAP1/TOR1A spectrum F006 — frequency
36648081 Chinese isolated dystonia WES F006
19908325 THAP1 screening Italy F006 — upper-body
34802187 D2 receptor deficits Thap1 null F007 — indirect pathway
35015830 THAP1 regulates SP1 family F007 — SP1/SP4
17003378 THAP1 pRB/E2F cell cycle F008
20200153 THAP1–HCF-1–OGT (DYT6↔DYT3) F008
31117876 Emerging dystonia therapies F009
40841848 Generalized dystonia treatment F009 — algorithm
27188707 Dystonia mutations in spasmodic dysphonia F010
28186656 Genotype-specific structure in SD F010
33638639 VAChT disrupted in DYT1 F010 — network
22377579 THAP1 genotype-phenotype F011 — onset 16.8y
39732371 Nerve injury two-hit + omics F011, F012
31367947 Cerebellar involvement DYT-THAP1 F012
42371050 Late-onset THAP1 spectrum F012

Corroborating / contextual: 21793105 (UMD-THAP1 LSDB), 22652465 (subcellular localization + DTI), 20010837 (bipartite DNA recognition), 38737544 (neuron–glia regulatory network), 27913194 (India cohort), 27093447 (GNAL differential), 40879515 (DYT-PRKRA differential).

Limitations and Knowledge Gaps

  • No overt dystonia in animal models. Thap1 rodents recapitulate molecular and motor phenotypes but not overt dystonia, limiting mechanistic and preclinical therapeutic testing (F007). The genotype-to-dystonia gap is unresolved.
  • Incomplete penetrance unexplained. The 40–60% penetrance implies unidentified genetic modifiers and/or environmental triggers (F011). No protective alleles are known.
  • Sparse quantitative epidemiology. Absolute prevalence/incidence of DYT6 are not well established; estimates derive from proportions within dystonia cohorts (F006).
  • No disease-specific biomarker or QoL instrument. Diagnosis is genetic; no fluid biomarker or DYT6-tailored QoL measure exists.
  • Human GxE evidence is indirect. The two-hit model is demonstrated only in mice; a peripheral-injury trigger in humans is plausible but unproven (F012).
  • DBS response variability. Predictors of GPi-DBS response in DYT6 and mechanisms of late partial regression are incompletely understood (F003).
  • No disease-modifying therapy. All treatments are symptomatic; gene- or transcription-targeted therapeutics remain conceptual.

Proposed Follow-up Experiments / Actions

  1. Modifier-gene / penetrance study. Genome-wide or targeted analysis comparing manifesting vs non-manifesting THAP1 carriers within families to identify penetrance modifiers (addresses F011).
  2. Improved dystonia models. Develop conditional/humanized Thap1 models (cell-type-specific in striatal D2 neurons and deep cerebellar nuclei) with sensitized ("second-hit") paradigms to elicit overt dystonia and test the branch-specific model (F007, F012).
  3. Single-cell / spatial transcriptomics of striatum and cerebellum in Thap1 models to map SP1/SP4-dependent, cell-type-specific dysregulation and pinpoint the causal node between transcriptional change and circuit dysfunction (F007).
  4. Prospective DBS-response registry stratified by THAP1 genotype (truncating vs THAP-domain missense vs other) to define predictors and characterize late regression (F003, F011).
  5. Human GxE investigation. Retrospective/prospective analysis of whether peripheral trauma or metabolic stress precedes symptom onset in THAP1 carriers, translating the mouse two-hit finding (F012).
  6. Therapeutic proof-of-concept. Test dosage-restoring or SP1/SP4-network-normalizing strategies (e.g., ASO/gene supplementation) in models, given the loss-of-function, transcription-network mechanism (F001, F002, F007).
  7. Biomarker discovery. Evaluate energy-metabolism/metabolomic signatures (from the two-hit omics study) as candidate peripheral biomarkers of disease activity or penetrance (F012).

Report compiled from 12 confirmed findings and 49 reviewed papers over 5 investigation iterations. All mechanistic and clinical claims are cited to primary literature (PMID). Evidence source types span human clinical/genetic cohorts, engineered rodent/cellular models, in-vitro biochemistry/structural biology, and neuroimaging.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 37
Resolved 37
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 37
On topic 27
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 29
Resolved 27
Unresolved (possible confabulation) 1
Obsolete 0
Unverifiable 1
Terms whose name was checked 15
Terms named correctly 5
Terms named as a different term 6
Terms whose name is worth a second look 4

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • HP:0002408 (1 mention) - the report calls it "Torticollis"; HP calls it Cerebral arteriovenous malformation
  • HP:0001350 (1 mention) - the report calls it "Dysphonia"; HP calls it Slurred speech
  • HP:0001260 (1 mention) - the report calls it "Symptom"; HP calls it Dysarthria
  • HP:0007325 (1 mention) - the report calls it "Clinical sign"; HP calls it Generalized dystonia
  • NCIT:C1084 (1 mention) - the report calls it "botulinum toxin"; NCIT calls it Staphylococcal Enterotoxin B
  • NCIT:C38150 (1 mention) - the report calls it "deep brain stimulation"; NCIT calls it PEComa

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

  • HP:0004350 (1 mention), reported as "Clinical sign" - HP does not contain this term

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • GO:0006355 (1 mention) - the report calls it "regulation of transcription"; GO calls it regulation of DNA-templated transcription
  • GO:0000122 (1 mention) - the report calls it "negative regulation of transcription by RNA pol II"; GO calls it negative regulation of transcription by RNA polymerase II
  • CL:0002613 (2 mentions) - the report calls it "striatal neuron"; CL calls it striatum neuron
  • UBERON:0002420 (1 mention) - the report calls it "Primary regions: Basal ganglia"; UBERON calls it basal ganglion**, and lists "basal ganglia" among its other names